: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bacterial Infections and Mycoses

Free Subscription

Articles published in Antimicrob Agents Chemother
Retrieve available abstracts of 539 articles:
HTML format

Single Articles

July 2026

BEADELL B, Yi S, Roberts M, Mun KS, et al
Using a liver-on-chip model to evaluate the effects of vancomycin and daptomycin on host immunometabolism and clearance of intracellular reservoirs of Staphylococcus aureus during bacteremia.
Antimicrob Agents Chemother. 2026 Jul 23:e0025426. doi: 10.1128/aac.00254.
PubMed Abstract available

PRICE E, Nmaju A, Faozia S, Lamb CL, et al
A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection.
Antimicrob Agents Chemother. 2026 Jul 17:e0057526. doi: 10.1128/aac.00575.
PubMed Abstract available

RABODOARIVELO MS, Galizia J, Recchia D, Stamilla A, et al
In vitro characterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2026 Jul 13:e0026026. doi: 10.1128/aac.00260.
PubMed Abstract available

CALDERIN JM, Wasserman S, Antilus-Sainte R, Cristaldo M, et al
Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.
Antimicrob Agents Chemother. 2026 Jul 10:e0026126. doi: 10.1128/aac.00261.
PubMed Abstract available

BRUNING-BARRY R, Ambroso JL, Yang X, Hickman D, et al
Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.
Antimicrob Agents Chemother. 2026 Jul 10:e0034326. doi: 10.1128/aac.00343.
PubMed Abstract available

PETERSIEL N, Howden BP, Giulieri S, Tong SYC, et al
An Achilles' heel for methicillin-resistant Staphylococcus aureus? Re-evaluating beta-lactam susceptibility of MRSA.
Antimicrob Agents Chemother. 2026 Jul 6:e0037426. doi: 10.1128/aac.00374.
PubMed Abstract available

HUANG Y-T, Kao C-Y, Kuo H-Y, Kao L-T, et al
Molecular epidemiology and emerging tet(X)-associated resistance of Elizabethkingia spp. in Taiwan, 2016-2022.
Antimicrob Agents Chemother. 2026;70:e0038726.
PubMed Abstract available

LASS-FLORL C, Steixner S, Bauer A, Meis JF, et al
Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review.
Antimicrob Agents Chemother. 2026;70:e0026326.
PubMed Abstract available

LAMOTH F
New Perspectives on Antimicrobial Agents: Fosmanogepix.
Antimicrob Agents Chemother. 2026;70:e0032426.
PubMed Abstract available

XU J, Fu P, Xu H-M, Jing C-M, et al
Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024.
Antimicrob Agents Chemother. 2026;70:e0003126.
PubMed Abstract available

JEHANNE Q, Aptel J, Ducournau A, Benejat L, et al
Contributions of whole-genome sequencing to the epidemiological monitoring of Campylobacter spp. in France.
Antimicrob Agents Chemother. 2026;70:e0019326.
PubMed Abstract available

SHAH S, Smith J, Smith BJ, Shields RK, et al
Evaluation of combination therapy duration for endocarditis secondary to Enterobacterales.
Antimicrob Agents Chemother. 2026;70:e0035726.
PubMed Abstract available

GIULIANO S, Gaibani P, Tascini C
Case Commentary: When susceptibility is not enough in recurrent Burkholderia cenocepacia infection.
Antimicrob Agents Chemother. 2026;70:e0046726.
PubMed Abstract available

GAGLANI B, Andermann TM, Wate C, Oldan J, et al
Sulbactam-durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz-Hugh-Curtis syndrome.
Antimicrob Agents Chemother. 2026;70:e0154225.
PubMed Abstract available

June 2026

TERLECKY AJ, Thom KV, Kan VW, Jiang J, et al
Genomic diversity and topical antimicrobial resistance in Staphylococcus aureus from clinical and carriage populations in the New York-New Jersey region.
Antimicrob Agents Chemother. 2026 Jun 30:e0065426. doi: 10.1128/aac.00654.
PubMed Abstract available

DE VOS MGJ, Jansen V, El Bouhlali O, Vlasblom AA, et al
Pyocyanin produced by Pseudomonas aeruginosa creates legacy effects that promote antibiotic resistance evolution in enterococci.
Antimicrob Agents Chemother. 2026 Jun 22:e0007826. doi: 10.1128/aac.00078.
PubMed Abstract available

DYCK KV, Hoogenkamp MA, Eichenseher F, Van Dijck P, et al
Phage-derived endolysin prevents dissemination of methicillin resistant Staphylococcus aureus during oral co-infection with Candida albicans.
Antimicrob Agents Chemother. 2026 Jun 15:e0181225. doi: 10.1128/aac.01812.
PubMed Abstract available

CHEN X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, et al
Ethionamide versus ethambutol-containing first-line regimens for TB meningitis.
Antimicrob Agents Chemother. 2026 Jun 15:e0019026. doi: 10.1128/aac.00190.
PubMed Abstract available

COLLAR GDS, Dornelles LS, Salvador JC, Pinto JB, et al
Consistent in vitro activity of sulbactam-durlobactam against genetically diverse carbapenem-resistant Acinetobacter baumannii in a high-endemic Brazilian setting.
Antimicrob Agents Chemother. 2026 Jun 12:e0010926. doi: 10.1128/aac.00109.
PubMed Abstract available

MIYASHITA N, Ogata M, Fukuda N, Yamura A, et al
Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia.
Antimicrob Agents Chemother. 2026 Jun 11:e0002526. doi: 10.1128/aac.00025.
PubMed Abstract available

QI C, Zhang R, Qu X, Liu X, et al
Nemonoxacin pharmacokinetics/pharmacodynamics against Escherichia coli in an in vitro dynamic urinary tract infection model.
Antimicrob Agents Chemother. 2026 Jun 11:e0136825. doi: 10.1128/aac.01368.
PubMed Abstract available

NOLAN AC, Kelly JB, Ahn J, Shinde D, et al
The beta-lactam adjuvant guanosine potentiates anti-folate antibiotics and pyrimidine synthesis inhibitors by depleting thymidine in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2026 Jun 10:e0037726. doi: 10.1128/aac.00377.
PubMed Abstract available

SUN W, Tian M, Wang X, Jiang S, et al
The protective effect of Schisandrin C against methicillin-resistant Staphylococcus aureus-induced otitis media.
Antimicrob Agents Chemother. 2026 Jun 10:e0009526. doi: 10.1128/aac.00095.
PubMed Abstract available

BARKER KS, Santana DJ, Zhang Q, Peters TL, et al
Correction for Barker et al., "Mutations in TAC1B drive CDR1 and MDR1 expression and azole resistance in Candida auris".
Antimicrob Agents Chemother. 2026 Jun 4:e0150725. doi: 10.1128/aac.01507.
PubMed

CALISE DG, Michaelis ML, Park SC, Wagner AS, et al
ZfpA-regulated chitin synthesis in Aspergillus fumigatus hyphae determines fungicidal tip lysis by FksA-targeting antifungals.
Antimicrob Agents Chemother. 2026 Jun 4:e0176925. doi: 10.1128/aac.01769.
PubMed Abstract available

WIEDERHOLD NP, Patterson HP, Sanders C, Canete-Gibas C, et al
Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides, Scopulariopsis/Microascus, Rasamsonia, and Purpureocillium species, including strains with in vitro resistance to other antifungals.
Antimicrob Agents Chemother. 2026 Jun 4:e0047626. doi: 10.1128/aac.00476.
PubMed Abstract available

YUSUFF H, Gadsby J, Isgro G, Zochios V, et al
Time-varying voriconazole clearance during extracorporeal membrane oxygenation.
Antimicrob Agents Chemother. 2026;70:e0009826.
PubMed Abstract available

KUNZ COYNE AJ, Judd C, Lucas K, Al Musawa M, et al
Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.
Antimicrob Agents Chemother. 2026;70:e0026826.
PubMed Abstract available

WALKER MM, Roberts JA, Li Y, Naicker S, et al
Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study.
Antimicrob Agents Chemother. 2026;70:e0137725.
PubMed Abstract available

MENIF B, Worley JN, Ben Mansour N, Mahjoubi F, et al
Leveraging the global genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae to inform infection prevention in Tunisian hospitals.
Antimicrob Agents Chemother. 2026;70:e0014226.
PubMed Abstract available

SETH-SMITH HMB, Greutmann M, Findlay J, Beckmann C, et al
Investigation of VIM-1-producing Enterobacter spp. across Switzerland: clonal dissemination and plasmid transmission.
Antimicrob Agents Chemother. 2026;70:e0182725.
PubMed Abstract available

KIKSTRA N, Beek SWv, Maartens G, Brust JCM, et al
Bedaquiline reloading strategies following interruptions during daily dosing.
Antimicrob Agents Chemother. 2026;70:e0006326.
PubMed Abstract available

TSAI M-H, Chen W-P, Chen C-L, Siu LK, et al
Treatment outcomes of combination versus monotherapy in Stenotrophomonas maltophilia bacteremia: a retrospective single-center analysis.
Antimicrob Agents Chemother. 2026;70:e0129725.
PubMed Abstract available

COSTE A, Paccoud O, Danion F, Conrad A, et al
A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials.
Antimicrob Agents Chemother. 2026;70:e0152325.
PubMed Abstract available

YI Q-L, Xu K-W, Guo P-H, Li L, et al
Surveillance for invasive candidiasis in China (CHIF-NET 2018-2021): rising antifungal resistance observed in a nationwide longitudinal study.
Antimicrob Agents Chemother. 2026;70:e0003526.
PubMed Abstract available

DAVIS KP, Poonawala H, Murphy C, Thorpe C, et al
Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates.
Antimicrob Agents Chemother. 2026;70:e0154725.
PubMed Abstract available

LEE A, Liu C, Tran MT, Phal S, et al
Population pharmacokinetics and safety of continuous oxacillin in preterm and term neonates and infants.
Antimicrob Agents Chemother. 2026;70:e0177725.
PubMed Abstract available

WU M, Chen Y, Su M, Wu H, et al
Domestic travel as a driver for the dissemination of mcr-1 in healthy travelers in China: a prospective, genomic epidemiological and gut microbiome study.
Antimicrob Agents Chemother. 2026;70:e0174625.
PubMed Abstract available

GUPTA R, Simcox BS, Rohde KH
CRISPRi-mediated in vivo gene silencing: a tool for prioritizing drug targets in Mycobacterium abscessus.
Antimicrob Agents Chemother. 2026;70:e0188925.
PubMed Abstract available

MATEO-VARGAS MA, Fernandez-Cuenca F, Lopez-Cerero L, Rodriguez-Iglesias M, et al
Description of a chromosomal fosA6 tandem multicopy fragment and its in vivo evolution in consecutive KPC-producing Klebsiella pneumoniae clinical isolates.
Antimicrob Agents Chemother. 2026;70:e0187725.
PubMed Abstract available

TAO X, Zhou Y, Xu S, Su Y, et al
Population pharmacokinetics and exposure-response analysis of levofloxacin in Chinese pediatric patients with severe refractory Mycoplasma pneumoniae pneumonia.
Antimicrob Agents Chemother. 2026;70:e0185325.
PubMed Abstract available

May 2026

AMUSIN DB, Simons LM, Garcia DS, Gatesy SWM, et al
Identification of Streptococcus pyogenes isolates with reduced beta-lactam susceptibility in a cohort of children with pharyngitis.
Antimicrob Agents Chemother. 2026 May 29:e0035426. doi: 10.1128/aac.00354.
PubMed Abstract available

DEKA N, Brauer AL, Connerton K, Hanson BM, et al
Pangenome analysis of Proteus mirabilis reveals lineage-specific antimicrobial resistance profiles and discordant genotype-phenotype correlations.
Antimicrob Agents Chemother. 2026 May 29:e0176825. doi: 10.1128/aac.01768.
PubMed Abstract available

VAHEDI-SHAHANDASHTI R, Nickel A-S, Eisele D, Lass-Florl C, et al
Can voriconazole gradient diffusion testing results be extrapolated to isavuconazole and posaconazole in Aspergillus spp.? Comparative analysis with CLSI broth microdilution and cyp51A gene sequencing.
Antimicrob Agents Chemother. 2026 May 15:e0181325. doi: 10.1128/aac.01813.
PubMed Abstract available

YOON MH, Culviner PH, Pereira Moraes M, Nitta H, et al
Strain diversity drives heterogeneous responses to tuberculosis combination therapy.
Antimicrob Agents Chemother. 2026 May 15:e0184925. doi: 10.1128/aac.01849.
PubMed Abstract available

GOTTESDIENER LS, Li Y, Greenwood-Quaintance KE, Komarow L, et al
Resistance to novel beta-lactam/beta-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.
Antimicrob Agents Chemother. 2026 May 15:e0038825. doi: 10.1128/aac.00388.
PubMed Abstract available

CAI G, Zhang Z
Global surveillance of Candida albicans: MIC distributions, resistance patterns, and temporal trends from the Antimicrobial Testing Leadership and Surveillance program (2015-2024).
Antimicrob Agents Chemother. 2026 May 12:e0161725. doi: 10.1128/aac.01617.
PubMed Abstract available

SINGH S, Shrivastava A, Boorgula GD, Long MC, et al
Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease.
Antimicrob Agents Chemother. 2026;70:e0143725.
PubMed Abstract available

DORAZIO AJ, Kline EG, Squires KM, Shah S, et al
Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel beta-lactams.
Antimicrob Agents Chemother. 2026;70:e0191025.
PubMed Abstract available

POONAWALA H, Davis K, Kenny ME, Alivisatos A, et al
Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum.
Antimicrob Agents Chemother. 2026;70:e0187625.
PubMed Abstract available

STELLFOX ME, Doi Y
Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in Escherichia coli.
Antimicrob Agents Chemother. 2026;70:e0005326.
PubMed Abstract available

DOS SANTOS AR, Bonifaz A, Bombassaro A, Machado ACdS, et al
Establishment of epidemiological cutoff values for clinically relevant Sporothrix species using CLSI-broth microdilution.
Antimicrob Agents Chemother. 2026;70:e0190725.
PubMed Abstract available

LIU C, Xie X, Sun M, Hang P, et al
Analysis of interactions between posaconazole/voriconazole and venetoclax.
Antimicrob Agents Chemother. 2026;70:e0110125.
PubMed Abstract available

LE ROY C, Guiraud J, Byambaa O, Balcon C, et al
In vitro selection and characterization of resistance to pristinamycin in Mycoplasma genitalium.
Antimicrob Agents Chemother. 2026;70:e0009426.
PubMed Abstract available

PEREZ-RODRIGUEZ G, Aja-Macaya P, Gonzalez-Pinto L, Taltavull B, et al
Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/beta-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.
Antimicrob Agents Chemother. 2026;70:e0165725.
PubMed Abstract available

SCHRADER SM, Pearson Z, Taffner S, Kanjilal S, et al
Prevalence and genetics of cefepime resistance among the AmpC-producing organisms Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes.
Antimicrob Agents Chemother. 2026;70:e0166125.
PubMed Abstract available

ZHOU M, Yang Z, Wang M, Jia R, et al
Identification and characteristics of a novel acquired aminoglycoside phosphotransferase, APH(3')-IVb, from Riemerella anatipestifer.
Antimicrob Agents Chemother. 2026;70:e0163125.
PubMed Abstract available

ROYER G, Danjean M, Rodriguez C, Fihman V, et al
Piperacillin-tazobactam resistance in Klebsiella pneumoniae is often associated with IS26-mediated bla(SHV-1) amplification in a widespread Klebsiella-adapted plasmid.
Antimicrob Agents Chemother. 2026;70:e0168225.
PubMed Abstract available

KARABA SM, Hareza DA, Munita JM, Martinez JRW, et al
Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.
Antimicrob Agents Chemother. 2026;70:e0160225.
PubMed Abstract available

SHROPSHIRE WC, Borjan J, Fonseca IY, Pham K, et al
Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli.
Antimicrob Agents Chemother. 2026;70:e0186025.
PubMed Abstract available

FABRIZIO C, Valzano F, Giuliano S, Morelli E, et al
Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: "going the extra mile".
Antimicrob Agents Chemother. 2026;70:e0088725.
PubMed Abstract available

VERDEJO MA, Malano-Barletta D, Pitart C, Hernandez-Meneses M, et al
Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy in Staphylococcus aureus bacteremia.
Antimicrob Agents Chemother. 2026 May 4:e0012826. doi: 10.1128/aac.00128.
PubMed Abstract available

April 2026

XIAO W, Fang T, Guan J, Ren J, et al
LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections.
Antimicrob Agents Chemother. 2026 Apr 30:e0173025. doi: 10.1128/aac.01730.
PubMed Abstract available

CUMMINGS JE, Woolhiser LK, Guglielmi V, Romano A, et al
Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model.
Antimicrob Agents Chemother. 2026 Apr 29:e0195325. doi: 10.1128/aac.01953.
PubMed Abstract available

KUTSCHER HL, Tamblin M, Kenney P, Reynolds JL, et al
Weekly pulmonary delivery of beta-glucan-chitosan-poly(lactic co-glycolic) acid (beta-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice.
Antimicrob Agents Chemother. 2026 Apr 20:e0028126. doi: 10.1128/aac.00281.
PubMed Abstract available

XU Y, Chen L, Liu J, Wang Q, et al
Fluconazole-induced liver injury in patients with pulmonary cryptococcosis: a comprehensive study integrating clinical cohort analysis, network toxicology, molecular docking, and transcriptomics.
Antimicrob Agents Chemother. 2026 Apr 20:e0197625. doi: 10.1128/aac.01976.
PubMed Abstract available

YANG Z, Zhang Y, Li D, Wang S, et al
Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro via enhanced ROS release.
Antimicrob Agents Chemother. 2026 Apr 17:e0164525. doi: 10.1128/aac.01645.
PubMed Abstract available

GARCIA-RIVERA C, Roda-Garcia JJ, Rodriguez JC, Molina-Pardines C, et al
Bridging clinical and environmental reservoirs: antimicrobial resistance in the emerging pathogen Shewanella algae.
Antimicrob Agents Chemother. 2026 Apr 15:e0189125. doi: 10.1128/aac.01891.
PubMed Abstract available

BAILEY DC, Castaneda-Barba S, Barry KE, Treerat P, et al
In vivo evolution of resistance to contemporary beta-lactam/beta-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection.
Antimicrob Agents Chemother. 2026;70:e0165125.
PubMed Abstract available

WU H, Cheng Z, Ding F, Hua J, et al
Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia.
Antimicrob Agents Chemother. 2026;70:e0103325.
PubMed Abstract available

TAKEMOTO K, Kamada M, Matsushita K, Matsui H, et al
Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model.
Antimicrob Agents Chemother. 2026;70:e0185225.
PubMed Abstract available

JEAN-PIERRE V, Moulieras M, Pantel A, Aujoulat F, et al
Molecular basis of linezolid resistance in Finegoldia spp. from orthopedic infections.
Antimicrob Agents Chemother. 2026;70:e0170225.
PubMed Abstract available

LEPAK AJ, Zhu Y, Andes DR
Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens.
Antimicrob Agents Chemother. 2026;70:e0188025.
PubMed Abstract available

SINGH N, Jogan CML, Zang Y, Shan X, et al
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model.
Antimicrob Agents Chemother. 2026;70:e0136525.
PubMed Abstract available

HONG Y-P, Liao Y-S, Chen B-H, Wang Y-W, et al
Epidemiology and genomics of azithromycin-resistant extensively drug-resistant Salmonella enterica serovar Typhimurium in Taiwan.
Antimicrob Agents Chemother. 2026;70:e0133425.
PubMed Abstract available

YAGI A, Shinohara M, Minato Y, Uchida R, et al
Establishment of an in vivo-based assay using a silkworm infection model for phenotypic evaluation of antimicrobial drug combinations against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2026;70:e0166525.
PubMed Abstract available

KOBASUK L, Cisowska T, Howard K, Gabriel C, et al
Clinical outcomes with oral cephalosporins as definitive treatment of Enterobacterales bacteremia from a urinary source based on cefazolin minimum inhibitory concentration.
Antimicrob Agents Chemother. 2026;70:e0135725.
PubMed Abstract available

March 2026

ZHANG Y, Han Y, Cao D, Yuan X, et al
Nitroxoline exerts potent anti-Aspergillus fumigatus activity by disrupting copper homeostasis and inducing oxidative stress.
Antimicrob Agents Chemother. 2026 Mar 31:e0183125. doi: 10.1128/aac.01831.
PubMed Abstract available

XI B, Wu Y
Peroxin Pex8 couples stress responses, antifungal tolerance, and virulence regulation in Candida albicans.
Antimicrob Agents Chemother. 2026 Mar 24:e0166225. doi: 10.1128/aac.01662.
PubMed Abstract available

KRANKEL L, Hauser J, Slavetinsky J, Zinser A, et al
Polygenic, cell-envelope adaptations drive high-frequency daptomycin resistance in Staphylococcus capitis NRCS-A from neonatal sepsis and NEC.
Antimicrob Agents Chemother. 2026 Mar 24:e0141425. doi: 10.1128/aac.01414.
PubMed Abstract available

ZHANG Y, Tang Y, Zhou Y, Wu H, et al
Safety and efficacy of echinocandin antifungal agents in Candida albicans endophthalmitis.
Antimicrob Agents Chemother. 2026 Mar 23:e0167025. doi: 10.1128/aac.01670.
PubMed Abstract available

SANCHEZ-OSUNA M, Bierge P, Gomez-Sanchez I, Guitart-Matas J, et al
Single point mutations in global regulatory genes restore cephalosporin resistance in a low-MIC Enterococcus faecium natural isolate.
Antimicrob Agents Chemother. 2026 Mar 23:e0194825. doi: 10.1128/aac.01948.
PubMed Abstract available

ARASTEHFAR A, Daneshnia F, Hovhannisyan H, Cabrera N, et al
Multidimensional assessment of in-host fitness costs of echinocandin resistance in the opportunistic fungal pathogen Candida glabrata reveals the niche-specific requirement for FKS1 and FKS2 during infection and gut colonization.
Antimicrob Agents Chemother. 2026 Mar 23:e0180125. doi: 10.1128/aac.01801.
PubMed Abstract available

SANTANA DJ, Cauldron NC, Rogers PD, Cuomo CA, et al
Deciphering the multidrug resistance paradigm in Candida auris.
Antimicrob Agents Chemother. 2026 Mar 16:e0106224. doi: 10.1128/aac.01062.
PubMed Abstract available

ARIAS CA, Tran TT, Kinsella P, Howden BP, et al
Reply to White and Siegrist, "Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges".
Antimicrob Agents Chemother. 2026 Mar 16:e0178525. doi: 10.1128/aac.01785.
PubMed

WHITE BP, Siegrist EA
Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges.
Antimicrob Agents Chemother. 2026 Mar 16:e0175325. doi: 10.1128/aac.01753.
PubMed

YAO L, Tian T, Zou D, Lu X, et al
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2026 Mar 11:e0170625. doi: 10.1128/aac.01706.
PubMed Abstract available

ABDELWAHAB MT, Svensson EM, Diacon AH, Conradie A, et al
Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.
Antimicrob Agents Chemother. 2026 Mar 9:e0139925. doi: 10.1128/aac.01399.
PubMed Abstract available

SAPORTA R, Nielsen EI, Menetrey A, Cameron DR, et al
Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Antimicrob Agents Chemother. 2026 Mar 4:e0095925. doi: 10.1128/aac.00959.
PubMed Abstract available

HANDELMAN M, Sarkar A, Varshavsky A, Shadkchan Y, et al
Directed evolution of the pathogenic mold Aspergillus fumigatus reveals novel genes contributing to triazole resistance.
Antimicrob Agents Chemother. 2026 Mar 4:e0163525. doi: 10.1128/aac.01635.
PubMed Abstract available

KARUNANIDHI A, Singh N, Watkins JV, Smith NM, et al
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-beta-lactamase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2026;70:e0154025.
PubMed Abstract available

SUBRTOVA P, Rozsivalova P, Halvova P, Malakova J, et al
Population pharmacokinetic model and dosing nomogram for daptomycin in adult patients with serious Gram-positive infections: emphasizing the role of loading doses and renal function-based adjustment.
Antimicrob Agents Chemother. 2026;70:e0153225.
PubMed Abstract available

JOUSSET AB, Girlich D, Oueslati S, Birer A, et al
In vivo selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing E. coli ST410.
Antimicrob Agents Chemother. 2026;70:e0133525.
PubMed Abstract available

LEHMAN D, Hetzler AE, Friedrich T, Strouse MM, et al
Variable chlorhexidine MICs across Klebsiella species from a single facility.
Antimicrob Agents Chemother. 2026;70:e0143625.
PubMed Abstract available

DOVE AS, Abdelsattar AS, Abutaleb NS, Seleem MN, et al
Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor of Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2026;70:e0123125.
PubMed Abstract available

BAI Y-M, Gao X-J, Yue C, Cai Z-P, et al
Salmonella Stanley ST29 carrying IncHI2/ST3-bla(NDM-5) plasmid emerged in a 4-month-old infant with diarrhea.
Antimicrob Agents Chemother. 2026;70:e0147125.
PubMed Abstract available

FAGUY FS, Walczak M, Barker BM
Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi.
Antimicrob Agents Chemother. 2026;70:e0122525.
PubMed Abstract available

CASADEVALL A, Kontoyiannis DP, van de Veerdonk FL
The International Immunotherapy Society for Fungal Diseases.
Antimicrob Agents Chemother. 2026;70:e0177425.
PubMed Abstract available

WANG J, Zhu J, Wu W, Luo R, et al
Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study.
Antimicrob Agents Chemother. 2026;70:e0128725.
PubMed Abstract available

DING R, Ma K, Zhang K, Liu J, et al
Broxyquinoline enhances antibacterial activity of colistin and attenuates LPS-induced inflammation.
Antimicrob Agents Chemother. 2026;70:e0139825.
PubMed Abstract available

IMOTO W, Abe J, Sakurai N, Kawamoto K, et al
Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model.
Antimicrob Agents Chemother. 2026;70:e0094425.
PubMed Abstract available

GONZALEZ-DIAZ A, Pinto M, Cadenas-Jimenez I, Duarte S, et al
First identification and molecular characterization of CTX-M-15 extended-spectrum beta-lactamase and OXA-9 beta-lactamase in Haemophilus influenzae in the Iberian Peninsula.
Antimicrob Agents Chemother. 2026;70:e0164925.
PubMed Abstract available

WIEDERHOLD NP, Najvar LK, Jaramillo R, Olivo M, et al
The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused by Coccidioides immitis.
Antimicrob Agents Chemother. 2026;70:e0146925.
PubMed Abstract available

PATEL M, Nieddu G, DeRyke CA, Young K, et al
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.
Antimicrob Agents Chemother. 2026;70:e0131325.
PubMed Abstract available

CARROLL AC, Mortimer L, Ghosh H, Reuter S, et al
Prediction of genetic relatedness of Escherichia coli using neighbor typing: a tool for rapid outbreak detection.
Antimicrob Agents Chemother. 2026;70:e0107125.
PubMed Abstract available

YANG X, Ning W, Yuan Y, Hou X, et al
Novel metabolic adaptation driven by glycoside hydrolase family 25 protein contributes to increasing trimethoprim-sulfamethoxazole resistance in clinical human Brucella melitensis isolates in China.
Antimicrob Agents Chemother. 2026;70:e0128425.
PubMed Abstract available

PONTIKIS K, Karaiskos I, Sakagianni A, Mouloudi E, et al
Comparative effectiveness of two antimicrobial regimens for the treatment of pan-drug-resistant Acinetobacter baumannii infections: results from the DESPAIR study.
Antimicrob Agents Chemother. 2026;70:e0115425.
PubMed Abstract available

MARANCHICK NF, Martyn-Dickens C, Enimil A, Yang H, et al
Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.
Antimicrob Agents Chemother. 2026 Mar 2:e0090925. doi: 10.1128/aac.00909.
PubMed Abstract available

February 2026

CHEN J, Sun Z, Su J, Li P, et al
Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
Antimicrob Agents Chemother. 2026 Feb 23:e0136225. doi: 10.1128/aac.01362.
PubMed Abstract available

ZHANG R, Zhang C, Liu J, Kong X, et al
Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models.
Antimicrob Agents Chemother. 2026 Feb 23:e0123725. doi: 10.1128/aac.01237.
PubMed Abstract available

WIEDERHOLD NP, Najvar LK, Jaramillo R, Olivo M, et al
The novel second-generation triterpenoid SCY-247 maintains in vitro and in vivo activity against resistant Candida glabrata.
Antimicrob Agents Chemother. 2026 Feb 19:e0162525. doi: 10.1128/aac.01625.
PubMed Abstract available

LI P, Xiao Y, Luo R, Zhang J, et al
Comparative genomic, phenotypic, and clinical characterization of ST11-KL25 and ST11-KL64 hypervirulent carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital, 2020-2023.
Antimicrob Agents Chemother. 2026 Feb 19:e0108025. doi: 10.1128/aac.01080.
PubMed Abstract available

DELLIS C, Laros G, Georgiou K, Zhang L, et al
Iotadentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2026 Feb 18:e0154525. doi: 10.1128/aac.01545.
PubMed Abstract available

LEE Y-L, Wang W-Y, Huang Y-T, Ho M-W, et al
In vitro activity of aztreonam-avibactam and distribution of carbapenemase genes in ceftazidime-avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019-2023.
Antimicrob Agents Chemother. 2026 Feb 18:e0154925. doi: 10.1128/aac.01549.
PubMed Abstract available

MA D, Arya R, Knapick BA, Sadaka NM, et al
Methicillin-resistant Staphylococcus aureus has phenotypic variation in mecA expression that alters antibiotic sensitivity.
Antimicrob Agents Chemother. 2026 Feb 12:e0039625. doi: 10.1128/aac.00396.
PubMed Abstract available

ALHOTHALI MT, Seemann T, Andersson P, Sherry N, et al
Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance.
Antimicrob Agents Chemother. 2026 Feb 4:e0152625. doi: 10.1128/aac.01526.
PubMed Abstract available

WANG J, Paroha R, Sha J, Verma AK, et al
Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection.
Antimicrob Agents Chemother. 2026;70:e0110525.
PubMed Abstract available

COLLINGS H, Stone M, Chrysostomou M, Hirst A, et al
A systematic literature review and (network) meta-analysis of the effectiveness of ceftolozane/tazobactam versus aminoglycosides/polymyxins and ceftazidime/avibactam for treating adult patients with multidrug-resistant Pseudomonas aeruginosa infection
Antimicrob Agents Chemother. 2026;70:e0073525.
PubMed Abstract available

WU Y, Han Q, Yang H, Xue J, et al
Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.
Antimicrob Agents Chemother. 2026;70:e0109525.
PubMed Abstract available

SASSMAN M, Karolak M, Dallaire M, Schaffer CE, et al
Beyond mecA: a two-tiered mechanism and regulatory rewiring drive high-level ceftaroline resistance in clinical MRSA.
Antimicrob Agents Chemother. 2026;70:e0058625.
PubMed Abstract available

MOHAMMAD S, Al Namer Y, Rahimeh W, Albalas M, et al
Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.
Antimicrob Agents Chemother. 2026;70:e0154625.
PubMed Abstract available

OMACHI R, Imai K, Sato A, Tanaka M, et al
Spread of dual-class drug-resistant Mycoplasma genitalium in Tokyo, Japan, 2023-2025.
Antimicrob Agents Chemother. 2026;70:e0136725.
PubMed Abstract available

FAN M, Zhang Z, Liu X, Deng L, et al
Phylogenetic diversification and fitness trade-offs of TetA variants in mediating eravacycline resistance in Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2026;70:e0067125.
PubMed Abstract available

BONCOMPAGNI SR, Antonelli A, Casciato B, Pieralli F, et al
NDM-63: a novel NDM metallo-beta-lactamase variant in the L3 loop, from a Klebsiella pneumoniae clinical isolate.
Antimicrob Agents Chemother. 2026;70:e0128625.
PubMed Abstract available

SHAH S, Clarke LG, Falcione BA, Shields RK, et al
Incidence and factors associated with rapid blood culture sterilization among patients receiving ertapenem combination therapy for MSSA bacteremia.
Antimicrob Agents Chemother. 2026;70:e0130325.
PubMed Abstract available

BOSIRE EM, Rather MA, Bell KE, Pavinski Bitar PD, et al
A recombinant lysogenic bacteriophage inhibits Salmonella virulence.
Antimicrob Agents Chemother. 2026;70:e0134125.
PubMed Abstract available

BAEZ-BARROSO G-A, Rodriguez-Coello A, Vazquez-Ucha JC, Lopez-Arguello S, et al
Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants.
Antimicrob Agents Chemother. 2026;70:e0120625.
PubMed Abstract available

IRELAND RE, Nunez A, Butcher W, Davies C, et al
Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset.
Antimicrob Agents Chemother. 2026;70:e0123225.
PubMed Abstract available

LAMONT EA, Kordus SL, Howe MD, Jia Z, et al
Essential role of MHC II in the antitubercular efficacy of pyrazinamide.
Antimicrob Agents Chemother. 2026;70:e0126425.
PubMed Abstract available

GUMBO T, Boorgula GD, Srivastava S
Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in Mycobacterium kansasii lung disease.
Antimicrob Agents Chemother. 2026;70:e0144725.
PubMed Abstract available

LOPEZ CL, Rerolle G, Snyder S, Arias O, et al
An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of Klebsiella pneumoniae pneumonia.
Antimicrob Agents Chemother. 2026;70:e0036325.
PubMed Abstract available

SONG Y, Buil JB, Zoll J, Tehupeiory-Kooreman M, et al
Characteristics of individual cyp51A SNPs and combinations thereof impacting the azole phenotype in TR(34)-mediated resistance genotypes of Aspergillus fumigatus.
Antimicrob Agents Chemother. 2026 Feb 3:e0152825. doi: 10.1128/aac.01528.
PubMed Abstract available

January 2026

LEPAK A, Bhavnani SM, Castanheira M, Rubino CM, et al
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development.
Antimicrob Agents Chemother. 2026 Jan 30:e0164325. doi: 10.1128/aac.01643.
PubMed Abstract available

PEDRAS A, Amaral C, Conceicao C, Malta-Luis C, et al
The siderophore transporter Sit1 is involved in the uptake of caspofungin by Candida albicans.
Antimicrob Agents Chemother. 2026 Jan 29:e0123625. doi: 10.1128/aac.01236.
PubMed Abstract available

KANG HJ, Arrieta AC, Dhooge C, Kelemen A, et al
Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.
Antimicrob Agents Chemother. 2026 Jan 27:e0130525. doi: 10.1128/aac.01305.
PubMed Abstract available

SHARMA P, Dean D, Read TD
Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered.
Antimicrob Agents Chemother. 2026 Jan 26:e0170825. doi: 10.1128/aac.01708.
PubMed Abstract available

ZHOU W, Chen D, Dong X, Yang T, et al
Emergence and genomic adaptation of the globally disseminated ST2250 lineage within the Staphylococcus aureus complex.
Antimicrob Agents Chemother. 2026 Jan 26:e0162825. doi: 10.1128/aac.01628.
PubMed Abstract available

SORDELLO S, Brock L, Tagliavini A, Federico D, et al
A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model.
Antimicrob Agents Chemother. 2026 Jan 15:e0110925. doi: 10.1128/aac.01109.
PubMed Abstract available

FERNANDES C, Lemos F, Curado L, Victor BL, et al
Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae.
Antimicrob Agents Chemother. 2026 Jan 14:e0066625. doi: 10.1128/aac.00666.
PubMed Abstract available

KUTSCHER HL, Tamblin M, Smith E, Shah A, et al
Repeated pulmonary dosing of beta-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice.
Antimicrob Agents Chemother. 2026 Jan 14:e0148025. doi: 10.1128/aac.01480.
PubMed Abstract available

SHAO Y, Lan X, Zhang X, Wang L, et al
fosZ, a novel plasmid-borne fosfomycin resistance gene in Pseudomonas species, especially carbapenem-resistant Pseudomonas aeruginosa isolates.
Antimicrob Agents Chemother. 2026 Jan 14:e0075025. doi: 10.1128/aac.00750.
PubMed Abstract available

ANEKE CI, Shahegh SS, Freeman AF, Zerbe C, et al
Beyond Fumigatus: a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance.
Antimicrob Agents Chemother. 2026 Jan 13:e0118425. doi: 10.1128/aac.01184.
PubMed Abstract available

SAYADI H, Gregoire M, Fromage Y, Ksentini M, et al
Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing.
Antimicrob Agents Chemother. 2026;70:e0136325.
PubMed Abstract available

FRATONI AJ
Simulated endocardial vegetation model highlights the complexity of high-inoculum infections among beta-lactamase-producing organisms.
Antimicrob Agents Chemother. 2026;70:e0134025.
PubMed Abstract available

LACKNER M, Toepfer S, Keniya MV, Lax C, et al
The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus.
Antimicrob Agents Chemother. 2026;70:e0133725.
PubMed Abstract available

ECHTERHOF A, Dharmaraj T, Blankenberg P, Targ B, et al
Whole-body distribution of three Pseudomonas phages characterized by a translational physiologically based pharmacokinetic model.
Antimicrob Agents Chemother. 2026;70:e0150625.
PubMed Abstract available

SINGLEY CM, Kurumaddali A, Hoover JL
Pharmacokinetic and pharmacodynamic characterization of gepotidacin against Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh infection model.
Antimicrob Agents Chemother. 2026;70:e0117625.
PubMed Abstract available

VAN HELDEN SR, Bleick CR, Holger DJ, El Ghali A, et al
Impact of Pseudomonas aeruginosa biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity.
Antimicrob Agents Chemother. 2026;70:e0092525.
PubMed Abstract available

XIE Y, Jian S, Yue J, Wang C, et al
Vitamin C enhances corneal fungal infection treatment in mice via chemotaxis and anti-inflammation.
Antimicrob Agents Chemother. 2026;70:e0116525.
PubMed Abstract available

December 2025

LLORENTE J, Sempere J, Llamosi M, Perez-Garcia C, et al
Emergence of antibiotic-resistant pneumococcal serotypes causing invasive pneumococcal disease in children, Spain.
Antimicrob Agents Chemother. 2025 Dec 31:e0153025. doi: 10.1128/aac.01530.
PubMed Abstract available

LUO J, Liu M, Ai W, Zheng X, et al
Gtr9 mutation trades phage resistance for carbapenem sensitivity to potentiate phage-meropenem therapy against carbapenem-resistant Acinetobacter baumannii in vitro.
Antimicrob Agents Chemother. 2025 Dec 30:e0135525. doi: 10.1128/aac.01355.
PubMed Abstract available

CLARY J, Roberts JK, Hanna D, Tagliavini A, et al
A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosis.
Antimicrob Agents Chemother. 2025 Dec 29:e0110325. doi: 10.1128/aac.01103.
PubMed Abstract available

HINTERWIRTH A, Chen C, Yan D, Zhong L, et al
Co-selection of genetic antibiotic resistance in Streptococcus pneumoniae after repeated azithromycin mass drug administrations in Niger.
Antimicrob Agents Chemother. 2025 Dec 23:e0156225. doi: 10.1128/aac.01562.
PubMed Abstract available

XIE P, Zhou W, Luo J, Dai Y, et al
Isobavachalcone effectively inhibits the growth of Candida albicans.
Antimicrob Agents Chemother. 2025 Dec 19:e0079725. doi: 10.1128/aac.00797.
PubMed Abstract available

PARK J, Choi S, Jeon YR, Kim L-H, et al
Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection.
Antimicrob Agents Chemother. 2025 Dec 19:e0151125. doi: 10.1128/aac.01511.
PubMed Abstract available

MAHADEVAN R, Garcia E, Sharma R, Qiu H, et al
A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms.
Antimicrob Agents Chemother. 2025 Dec 19:e0078225. doi: 10.1128/aac.00782.
PubMed Abstract available

APPLEBACH E, Amburgey-Crovetti K, Bakotic WL, Adhikari TB, et al
Prevalence and diversity of antifungal resistance in Fusarium isolates across clinical and agricultural settings in the United States.
Antimicrob Agents Chemother. 2025;69:e0120825.
PubMed Abstract available

BLEICK CR, Van Helden SR, Berti AD, Richa R, et al
Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates.
Antimicrob Agents Chemother. 2025;69:e0069925.
PubMed Abstract available

JUAN C-H, Chou S-H, Chuang C, Lin S-N, et al
Carbapenems versus non-carbapenems as definitive treatment for hypervirulent Klebsiella pneumoniae bacteremia in Taiwan.
Antimicrob Agents Chemother. 2025;69:e0084625.
PubMed Abstract available

HAHN MM, Anderson MS, Snyder M, Du W, et al
Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques.
Antimicrob Agents Chemother. 2025;69:e0127825.
PubMed Abstract available

EDWARDS B, Ripperton R, Tilley A, Chastain DB, et al
Insights into current coccidioidomycosis therapeutic pathways.
Antimicrob Agents Chemother. 2025;69:e0146525.
PubMed Abstract available

NODARI CS, Bai Q, Cayo R, Streling AP, et al
ISAba1-mediated bla(ADC) disruption restores third-generation cephalosporin susceptibility in a clinical Acinetobacter baumannii isolate.
Antimicrob Agents Chemother. 2025;69:e0070725.
PubMed Abstract available

CADENAS-JIMENEZ I, Gonzalez-Diaz A, Berbel D, Costa-Primo R, et al
First report of a DIM-1-producing Pseudomonas aeruginosa in Spain: genomic characterization and resistance determinants.
Antimicrob Agents Chemother. 2025;69:e0131125.
PubMed Abstract available

HESELPOTH RD, Euler CW, Fischetti VA
Second-generation lysocins as therapeutics for treating Pseudomonas aeruginosa infections.
Antimicrob Agents Chemother. 2025;69:e0131225.
PubMed Abstract available

RODRIGUEZ-OCHOA JL, Sauco-Carballo C, Perez-Palacios P, Merino-Bohorquez V, et al
Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producing Klebsiella pneumoniae isolates in a hollow-fiber infection model.
Antimicrob Agents Chemother. 2025;69:e0094625.
PubMed Abstract available

ALVARADO-OROSCO N, Gomis-Font MA, Sastre-Femenia MA, Ribera Ortiz S, et al
First nationwide survey on Pseudomonas aeruginosa in Bolivia: susceptibility profiles, resistome, and genomic epidemiology.
Antimicrob Agents Chemother. 2025;69:e0116325.
PubMed Abstract available

WANGCHINDA W, Wu JY, Abbo LM, Ackley R, et al
Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE).
Antimicrob Agents Chemother. 2025;69:e0132525.
PubMed Abstract available

FU Y, Zhang Y, Zhao J, Xie J, et al
Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions.
Antimicrob Agents Chemother. 2025;69:e0089125.
PubMed Abstract available

SLAIN N, Lucas K, Kunz Coyne AJ
Comparison between cefepime and carbapenem therapy for deep-seated AmpC-producing Enterobacterales infections: a propensity-weighted retrospective cohort study.
Antimicrob Agents Chemother. 2025;69:e0092825.
PubMed Abstract available

VANACHAYANGKUL P, Ruamsap N, Caridha D, Imerbsin R, et al
Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025;69:e0093225.
PubMed Abstract available

PAI MP, Cojutti PG, Gatti M, Rinaldi M, et al
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?
Antimicrob Agents Chemother. 2025;69:e0121525.
PubMed Abstract available

GONZALEZ-PINTO L, Gomis-Font MA, Perez-Rodriguez G, Blanco-Martin T, et al
Contribution of mutational resistance mechanisms and acquired beta-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2025;69:e0104825.
PubMed Abstract available

UPTON CM, Calderin JM, Diacon AH, Boeree MJ, et al
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.
Antimicrob Agents Chemother. 2025;69:e0093125.
PubMed Abstract available

TAKEI K, Kanamori H, Sakata R, Ogawa M, et al
High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings.
Antimicrob Agents Chemother. 2025;69:e0095325.
PubMed Abstract available

CUI Y, Feng X, Wang J, Liu L, et al
Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.
Antimicrob Agents Chemother. 2025;69:e0097325.
PubMed Abstract available

BENAVENT E, Lora-Tamayo J, Ulldemolins M, Pons-Oltra P, et al
Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.
Antimicrob Agents Chemother. 2025;69:e0077325.
PubMed Abstract available

YOUSSEF EG, Gebremariam T, Gu Y, Patterson H, et al
Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates.
Antimicrob Agents Chemother. 2025 Dec 5:e0140025. doi: 10.1128/aac.01400.
PubMed Abstract available

ABDELSATTAR AS, Kikiowo B, Abutaleb NS, Dove AS, et al
Repurposing epetraborole to combat Neisseria gonorrhoeae and Chlamydia trachomatis infections.
Antimicrob Agents Chemother. 2025 Dec 5:e0144525. doi: 10.1128/aac.01445.
PubMed Abstract available

November 2025

FUNK OG, Li J, Khan I, Cusumano JA, et al
Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates.
Antimicrob Agents Chemother. 2025 Nov 24:e0105025. doi: 10.1128/aac.01050.
PubMed Abstract available

LAVOIE T, Sierra T, Daffinee K, Pogue JM, et al
Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.
Antimicrob Agents Chemother. 2025 Nov 19:e0090625. doi: 10.1128/aac.00906.
PubMed Abstract available

DARNELL RL, Knottenbelt MK, Rose OE, Cleary CSB, et al
Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in Enterococcus faecalis.
Antimicrob Agents Chemother. 2025 Nov 18:e0062925. doi: 10.1128/aac.00629.
PubMed Abstract available

HE G, Zeng S, Banki LT, Zhou W, et al
Clinical emergence of inducible macrolide resistance mediated by acquired erm(41) C28T mutation in Mycobacterium abscessus.
Antimicrob Agents Chemother. 2025 Nov 6:e0115325. doi: 10.1128/aac.01153.
PubMed Abstract available

KOCER K, My TN, Sy BT, Gopel L, et al
Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2025;69:e0085725.
PubMed Abstract available

ALSHIRAIHI IM, Lam H, Troyer BT, Tran KN, et al
Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening.
Antimicrob Agents Chemother. 2025;69:e0047525.
PubMed Abstract available

WIEDERHOLD NP
Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant Lomentospora prolificans infection in a child.
Antimicrob Agents Chemother. 2025;69:e0107225.
PubMed Abstract available

AOKI W, Uwamino Y, Kubota H, Kamoshita Y, et al
Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2025;69:e0075525.
PubMed Abstract available

POUYA N, Finch NA, Granillo A, Bhimraj A, et al
Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: a report of two cases.
Antimicrob Agents Chemother. 2025;69:e0067425.
PubMed Abstract available

COJUTTI PG, Pai MP, Gatti M, Rinaldi M, et al
Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion.
Antimicrob Agents Chemother. 2025;69:e0104225.
PubMed Abstract available

KUNZ COYNE AJ, Gray R, May E, Curry H, et al
Molecular and pharmacodynamic insights into beta-lactam therapy for high-inoculum Enterobacter cloacae complex infections.
Antimicrob Agents Chemother. 2025;69:e0117025.
PubMed Abstract available

WANG C, Feng Y, Zong Z
Colistin heteroresistance in Enterobacter due to base heterozygosity at certain phoP and phoQ locations.
Antimicrob Agents Chemother. 2025;69:e0071325.
PubMed Abstract available

LODISE TP, Min J, Nathanson BH, Yucel E, et al
Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA).
Antimicrob Agents Chemother. 2025;69:e0056925.
PubMed Abstract available

CHEN B, Chen Y, Chen M, Mao Y, et al
Population pharmacokinetics and Monte Carlo-based dosing optimization of trimethoprim-sulfamethoxazole.
Antimicrob Agents Chemother. 2025;69:e0051925.
PubMed Abstract available

FORTINI M, Jones TW, Grams TR, Mehra S, et al
Successful use of olorofim for the treatment of Lomentospora prolificans knee tendonitis, synovitis, and concomitant osteomyelitis in an immunocompetent child.
Antimicrob Agents Chemother. 2025;69:e0060225.
PubMed Abstract available

MOHAMAD M, Hurst MM, Elkrewi E, Randall CP, et al
Nature of bacitracin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2025 Nov 4:e0087525. doi: 10.1128/aac.00875.
PubMed Abstract available

October 2025

HODBERT E, Lemenand O, Thibaut S, Coeffic T, et al
Exploring multidrug resistance patterns in community-acquired Escherichia coli urinary tract infections with machine learning.
Antimicrob Agents Chemother. 2025 Oct 31:e0042225. doi: 10.1128/aac.00422.
PubMed Abstract available

SUN L, Lei T, Liu Y, Lu S, et al
In vivo development of elevated linezolid resistance mediated by a deletion in ribosomal protein L3 in clinical Enterococcus faecium.
Antimicrob Agents Chemother. 2025 Oct 28:e0087125. doi: 10.1128/aac.00871.
PubMed Abstract available

XING Y, Bian M, Huang X, Lv B, et al
Genome-wide screen reveals glycerol-induced aminoglycoside potentiation against Staphylococcus aureus via boosting GlpK-initiated energy metabolism.
Antimicrob Agents Chemother. 2025 Oct 23:e0093825. doi: 10.1128/aac.00938.
PubMed Abstract available

MARCH VFA, Zwyer M, Loiseau C, Brites D, et al
Variability in intrinsic drug tolerance in Mycobacterium tuberculosis corresponds with phylogenetic lineage.
Antimicrob Agents Chemother. 2025 Oct 21:e0099625. doi: 10.1128/aac.00996.
PubMed Abstract available

SHAW S, Pragasam AK, Chowdhury G, Samanta P, et al
Genomic portrayal of emerging carbapenem-resistant El Tor variant Vibrio cholerae O1.
Antimicrob Agents Chemother. 2025 Oct 17:e0074025. doi: 10.1128/aac.00740.
PubMed Abstract available

FRIAES A, Mamede R, Santos B, Marrao G, et al
Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef(A)-msr(D)/emm2-ST55 lineage in Portugal (2014-2019).
Antimicrob Agents Chemother. 2025 Oct 10:e0096825. doi: 10.1128/aac.00968.
PubMed Abstract available

ALVARADO CASAS ML, Triana Diaz JA, Montilla-Escudero E, Prada Cardozo DA, et al
Genomic epidemiology of Colombian resistant Candida auris isolates.
Antimicrob Agents Chemother. 2025 Oct 7:e0072525. doi: 10.1128/aac.00725.
PubMed Abstract available

DONG X, Xiang Y, Li Y, Zhang Y, et al
Lineage-specific evolution and resistance-virulence divergence in Klebsiella pneumoniae ST268: a global population genomic analysis.
Antimicrob Agents Chemother. 2025;69:e0070325.
PubMed Abstract available

MOJICA MF, Becka SA, Edwards M, Myers C, et al
Burkholderia pseudomallei PenI beta-lactamase and variants are potently inhibited by taniborbactam.
Antimicrob Agents Chemother. 2025;69:e0078725.
PubMed Abstract available

RAKA V, Jangra M, Kaur P, Dadwal R, et al
Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics.
Antimicrob Agents Chemother. 2025;69:e0108325.
PubMed Abstract available

ALARCON RIOS AC, Zwep LB, Vriesendorp B, Knibbe CAJ, et al
Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth.
Antimicrob Agents Chemother. 2025;69:e0042125.
PubMed Abstract available

WAN T-W, Shintani M, Kojima KK, Moriguchi N, et al
Transposition of Tn552-II (a Tn552 derivative) to the conjugative pCtra plasmid family in pediatric multidrug-resistant community-associated MRSA.
Antimicrob Agents Chemother. 2025;69:e0064725.
PubMed Abstract available

LI Y, Roberts JA, Abdul-Aziz MH, Sime FB, et al
Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials.
Antimicrob Agents Chemother. 2025;69:e0073225.
PubMed Abstract available

POGUE JM, Harrington J, Wangchinda W, Kaye KS, et al
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.
Antimicrob Agents Chemother. 2025;69:e0108624.
PubMed Abstract available

ZHANG Y, Guo S, Jiang L, Wang S, et al
Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV.
Antimicrob Agents Chemother. 2025;69:e0040525.
PubMed Abstract available

September 2025

PEROUTKA-BIGUS N, Scherman MS, Kaya F, Waidyarachchi SL, et al
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
Antimicrob Agents Chemother. 2025 Sep 30:e0118325. doi: 10.1128/aac.01183.
PubMed Abstract available

VENA A, Bartalucci C, Muccio M, Tiseo G, et al
Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections.
Antimicrob Agents Chemother. 2025 Sep 30:e0035525. doi: 10.1128/aac.00355.
PubMed Abstract available

SHINOHARA T, Wada A, Abe M, Oiki S, et al
A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant Candida auris infection.
Antimicrob Agents Chemother. 2025 Sep 26:e0085625. doi: 10.1128/aac.00856.
PubMed Abstract available

SINGH S, Devine M, Gumbo T, Srivastava S, et al
Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Sep 22:e0048125. doi: 10.1128/aac.00481.
PubMed Abstract available

RUPASINGHE P, Ismail N, Mulders W, Warren RM, et al
In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Sep 22:e0111325. doi: 10.1128/aac.01113.
PubMed Abstract available

BALDIN VP, Harding CL, Quach D, Sugie J, et al
Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Sep 22:e0098025. doi: 10.1128/aac.00980.
PubMed Abstract available

ZENG Q, Huang H, Lu J, Wu L, et al
Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study.
Antimicrob Agents Chemother. 2025 Sep 22:e0064425. doi: 10.1128/aac.00644.
PubMed Abstract available

WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo.
Antimicrob Agents Chemother. 2025 Sep 18:e0049225. doi: 10.1128/aac.00492.
PubMed Abstract available

MARTIN-VICENTE A, Nywening AV, Xie J, Thorn HI, et al
Genetic analysis of common triazole resistance mechanisms in a collection of Aspergillus lentulus clinical isolates from the United States.
Antimicrob Agents Chemother. 2025 Sep 12:e0069025. doi: 10.1128/aac.00690.
PubMed Abstract available

TURNER AM, Kinsella P, Miller WR, Carter GP, et al
Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.
Antimicrob Agents Chemother. 2025 Sep 11:e0106024. doi: 10.1128/aac.01060.
PubMed Abstract available

KIRUBAKAR G, Johnston L, Nae Rin Lee B, Russell DG, et al
Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Sep 11:e0079525. doi: 10.1128/aac.00795.
PubMed Abstract available

AVERY LM, Edwards M, Yi F, Moeck G, et al
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model.
Antimicrob Agents Chemother. 2025;69:e0001725.
PubMed Abstract available

CASTILLO-RAMIREZ S, Aguilar-Vera A, Kumar A, Evans B, et al
Acinetobacter baumannii: much more than a human pathogen.
Antimicrob Agents Chemother. 2025;69:e0080125.
PubMed Abstract available

FURLAN GHF, Oliveira DAS, Bertoluci DFDF, Gomes TA, et al
Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae.
Antimicrob Agents Chemother. 2025;69:e0031825.
PubMed Abstract available

RESENDIZ-GALVAN JE, Arora PR, Lokhande RV, Udwadia ZF, et al
Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
Antimicrob Agents Chemother. 2025 Sep 2:e0010125. doi: 10.1128/aac.00101.
PubMed Abstract available

August 2025

WALSH TJ, Coleman CI, Blissett R, Prawitz T, et al
Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective.
Antimicrob Agents Chemother. 2025 Aug 27:e0057025. doi: 10.1128/aac.00570.
PubMed Abstract available

ZHANG M, Allen R, Ames L, Engelhart CA, et al
Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Aug 19:e0036825. doi: 10.1128/aac.00368.
PubMed Abstract available

REITLER P, DeJarnette CA, Kumar R, Tucker KM, et al
A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans.
Antimicrob Agents Chemother. 2025 Aug 18:e0048425. doi: 10.1128/aac.00484.
PubMed Abstract available

BARKER KS, Santana DJ, Zhang Q, Peters TL, et al
Mutations in TAC1B drive increased CDR1 and MDR1 expression and azole resistance in Candida auris.
Antimicrob Agents Chemother. 2025 Aug 18:e0030025. doi: 10.1128/aac.00300.
PubMed Abstract available

MUSHER DM
Amoxicillin vs. ceftriaxone to treat pneumonia caused by amoxicillin-non-susceptible Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2025 Aug 13:e0078025. doi: 10.1128/aac.00780.
PubMed Abstract available

ISMAIL N, Sirgel F, Omar SV, Omar S, et al
Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.
Antimicrob Agents Chemother. 2025;69:e0035625.
PubMed Abstract available

LE MOIGNE V, Bitar M, Arthur M, Mainardi J-L, et al
The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination against Mycobacterium abscessus in a mouse model of infection.
Antimicrob Agents Chemother. 2025;69:e0053425.
PubMed Abstract available

BUYUKYANBOLU E, Argotsinger J, Beck ET, Chamberland RR, et al
Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study.
Antimicrob Agents Chemother. 2025;69:e0037925.
PubMed Abstract available

KUBIN CJ, Garzia C, Uhlemann A-C
Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025;69:e0106324.
PubMed Abstract available

GONG J-J, Huang I-H, Hung Y, Chen Y-W, et al
Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.
Antimicrob Agents Chemother. 2025;69:e0051525.
PubMed Abstract available

OJHA S, Chatterjee P, Beuria TK
Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant S. aureus.
Antimicrob Agents Chemother. 2025 Aug 4:e0032025. doi: 10.1128/aac.00320.
PubMed Abstract available

GOMI S, Price E, Burgoyne H, Faozia S, et al
Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.
Antimicrob Agents Chemother. 2025 Aug 4:e0046925. doi: 10.1128/aac.00469.
PubMed Abstract available

July 2025

VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
PubMed Abstract available

LIANG L, Quigley J, Theriault M, Iinishi A, et al
A chlorinated diketopiperazine antibiotic targets Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Jul 31:e0036925. doi: 10.1128/aac.00369.
PubMed Abstract available

WU Y, Dai Y, Lu H, Jiang X, et al
Osh2 mediates Candida species resistance to miltefosine by regulating zymosterol accumulation.
Antimicrob Agents Chemother. 2025 Jul 23:e0042725. doi: 10.1128/aac.00427.
PubMed Abstract available

BARKER KS, Patterson HP, Morschhauser J, Cuomo CA, et al
Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus).
Antimicrob Agents Chemother. 2025 Jul 23:e0068025. doi: 10.1128/aac.00680.
PubMed Abstract available

HIDROSOLLO JH, Liao H-W, Yap CH, James JJ, et al
Indolenine-substituted pyrazole derivative 4e inhibits planktonic Staphylococcus lugdunensis growth and biofilm formation by disrupting purine biosynthesis and compromising cell wall and membrane integrity.
Antimicrob Agents Chemother. 2025 Jul 23:e0019925. doi: 10.1128/aac.00199.
PubMed Abstract available

FANG Y, Song M, Zhang Y, Wu Z, et al
Evolution of XDR Pseudomonas aeruginosa ST463 strains with two plasmids harboring multiple antimicrobial resistance genes.
Antimicrob Agents Chemother. 2025 Jul 23:e0169724. doi: 10.1128/aac.01697.
PubMed Abstract available

YAMADA AY, de Souza AR, Madalosso G, de Assis DB, et al
Emergence of carbapenem-resistant Acinetobacter baumannii clonal complex 2 in multiple hospitals in Sao Paulo state, Brazil.
Antimicrob Agents Chemother. 2025 Jul 23:e0186524. doi: 10.1128/aac.01865.
PubMed Abstract available

TUANYOK A, Nakajima C, Noll T, Khan MSR, et al
Genomic insights into ceftazidime resistance in Burkholderia pseudomallei: discovery of A172T mutation and palindromic GC-rich repeat sequences facilitating penA duplication and amplification.
Antimicrob Agents Chemother. 2025 Jul 21:e0022025. doi: 10.1128/aac.00220.
PubMed Abstract available

TRUONG-BOLDUC QC, Wang Y, Lawton BG, Zweifach JJ, et al
NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2025 Jul 9:e0046025. doi: 10.1128/aac.00460.
PubMed Abstract available

HSU AJ, Tamma PD
Case Commentary: Overcoming intrinsic resistance-the successful use of aztreonam and avibactam for Stenotrophomonas maltophilia meningitis.
Antimicrob Agents Chemother. 2025 Jul 9:e0064025. doi: 10.1128/aac.00640.
PubMed Abstract available

CANFIELD GS, Chatterjee A, Espinosa J, Mangalea MR, et al
Correction for Canfield et al., "Lytic Bacteriophages Facilitate Antibiotic Sensitization of Enterococcus faecium".
Antimicrob Agents Chemother. 2025 Jul 8:e0059025. doi: 10.1128/aac.00590.
PubMed

CAMARA J, Grau I, Gonzalez-Diaz A, Santos N, et al
Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact.
Antimicrob Agents Chemother. 2025 Jul 8:e0023725. doi: 10.1128/aac.00237.
PubMed Abstract available

BELLO-LOPEZ E, Kawabata A, Cantero J, Mendoza S, et al
Genomic epidemiology reveals antibiotic resistance transfer and polyclonal dissemination of Acinetobacter baumannii in a Paraguayan hospital.
Antimicrob Agents Chemother. 2025 Jul 8:e0007725. doi: 10.1128/aac.00077.
PubMed Abstract available

VAN WART SA, Safir MC, Bhavnani SM, Lodise TP, et al
Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.
Antimicrob Agents Chemother. 2025;69:e0138224.
PubMed Abstract available

GATTI M, Rinaldi M, Cojutti PG, Bonazzetti C, et al
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-
Antimicrob Agents Chemother. 2025;69:e0048825.
PubMed Abstract available

HOU Y, Pi R, Jia J, Wu Z, et al
Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China.
Antimicrob Agents Chemother. 2025;69:e0184724.
PubMed Abstract available

JIA Y, Fan J, Tan Z, Li A, et al
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity.
Antimicrob Agents Chemother. 2025;69:e0024925.
PubMed Abstract available

PITCOCK C, Burgess DS, Olney KB
Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations.
Antimicrob Agents Chemother. 2025;69:e0185724.
PubMed Abstract available

ZHANG X, Liu F, Li S, Cheng Z, et al
Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure.
Antimicrob Agents Chemother. 2025;69:e0000425.
PubMed Abstract available

FERRREIRA CDO, Leturiondo AL, Dos Santos CG, da Silva JB, et al
Classic and new candidate markers for drug resistance in a large cohort of leprosy patients from the Amazon state, Brazil.
Antimicrob Agents Chemother. 2025;69:e0155024.
PubMed Abstract available

OUTEDA-GARCIA M, Garcia-Pose A, Guijarro-Sanchez P, Rodriguez-Coello A, et al
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025;69:e0194024.
PubMed Abstract available

YOO O, Salman S, Hla TK, Osowicki J, et al
Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic fever.
Antimicrob Agents Chemother. 2025;69:e0026925.
PubMed Abstract available

RAJAKANI SG, Xavier BB, Nguyen NM, Lin Q, et al
Characterization of genome-wide transpositions induced by colistin exposure in multi-drug-resistant Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2025;69:e0157424.
PubMed Abstract available

CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
PubMed Abstract available

VAHEDI-SHAHANDASHTI R, Moroder E, Lass-Florl C
Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel?
Antimicrob Agents Chemother. 2025 Jul 1:e0024125. doi: 10.1128/aac.00241.
PubMed Abstract available

June 2025

PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
Erratum for Peroutka-Bigus et al., "Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease".
Antimicrob Agents Chemother. 2025 Jun 26:e0065425. doi: 10.1128/aac.00654.
PubMed

ERDEM H, Sakir-Yildirim S, Ankarali H, Batirel A, et al
Managing Candida auris fungemias: the results of a prospective and international study.
Antimicrob Agents Chemother. 2025 Jun 25:e0035825. doi: 10.1128/aac.00358.
PubMed Abstract available

BOYD JM, Price EE, Roman Rodriguez F, Burchat N, et al
Treatment of Staphylococcus aureus with environmentally relevant concentrations of triclosan activates SaeRS-dependent virulence factor expression.
Antimicrob Agents Chemother. 2025 Jun 18:e0172824. doi: 10.1128/aac.01728.
PubMed Abstract available

AI Q, Wang S, Chen Z, Zheng S, et al
Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2025 Jun 18:e0160924. doi: 10.1128/aac.01609.
PubMed Abstract available

MELLETT M, Lawandi A, Caya C, Lee TC, et al
Antibiotic synergy against Staphylococcus aureus: a systematic review and meta-analysis.
Antimicrob Agents Chemother. 2025 Jun 17:e0119924. doi: 10.1128/aac.01199.
PubMed Abstract available

GONZALEZ-JIMENEZ I, Keniya MV, Aptekmann AA, Quinteros C, et al
Expression of 1,3-beta-glucan synthase subunits in Candida glabrata is regulated by the cell cycle and growth conditions and at both transcriptional and post-transcriptional levels.
Antimicrob Agents Chemother. 2025 Jun 17:e0050025. doi: 10.1128/aac.00500.
PubMed Abstract available

LEUS IV, Zgurskaya HI
No two are alike: on the role of Klebsiella pneumoniae permeability barriers in antibiotic susceptibility and persistence.
Antimicrob Agents Chemother. 2025 Jun 17:e0008525. doi: 10.1128/aac.00085.
PubMed Abstract available

MEEKES LM, Heikema AP, Tompa M, Astorga Alsina AL, et al
Proteogenomic analysis demonstrates increased bla(OXA-48) copy numbers and OmpK36 loss as contributors to carbapenem resistance in Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2025 Jun 13:e0010725. doi: 10.1128/aac.00107.
PubMed Abstract available

SUZUKI Y, Kawada-Matsuo M, Thuan VTT, Le MN-T, et al
D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility of Staphylococcus aureus.
Antimicrob Agents Chemother. 2025 Jun 12:e0193624. doi: 10.1128/aac.01936.
PubMed Abstract available

TSAI S, Grimes K
Case Commentary: A herculean effort for Mycobacterium heraklionense-localized azithromycin bead pharmacokinetics.
Antimicrob Agents Chemother. 2025;69:e0030525.
PubMed Abstract available

SHRIVASTAVA A, Singh S, Boorgula GD, Galvez R-A, et al
Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease.
Antimicrob Agents Chemother. 2025;69:e0003025.
PubMed Abstract available

GARBE E, Ullah A, Aldejohann AM, Kurzai O, et al
In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium.
Antimicrob Agents Chemother. 2025;69:e0191324.
PubMed Abstract available

VALADEZ A, Zurawska M, Harlan E, Scheetz MH, et al
Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO.
Antimicrob Agents Chemother. 2025;69:e0010225.
PubMed Abstract available

WAITES JT, Crabb DM, Ratliff AE, Waites KB, et al
Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023.
Antimicrob Agents Chemother. 2025;69:e0186824.
PubMed Abstract available

AL HROOT J, Reeder J, Yuan X, Gu K, et al
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.
Antimicrob Agents Chemother. 2025;69:e0186924.
PubMed Abstract available

BLERIOT I, Blasco L, Fernandez-Grela P, Fernandez-Garcia L, et al
Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512.
Antimicrob Agents Chemother. 2025;69:e0193524.
PubMed Abstract available

MATEO-VARGAS MA, Rodriguez-Pallares S, Arca-Suarez J, Lopez-Cerero L, et al
Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants.
Antimicrob Agents Chemother. 2025;69:e0149424.
PubMed Abstract available

DUBORG MIKKELSEN MK, Jorgensen AR, Dahl VN, Wejse CM, et al
Mycobacterium heraklionense hand tenosynovitis-a case description of a three-year treatment course and perioperative measurement of azithromycin target tissue concentrations.
Antimicrob Agents Chemother. 2025;69:e0167024.
PubMed Abstract available

WONG-SO J, Magreault S, Carbonnelle E, Jullien V, et al
Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2025 Jun 2:e0017225. doi: 10.1128/aac.00172.
PubMed Abstract available

May 2025

ARMESILLA-DIAZ A, Pilar Arenaz M, Ashby C, Blanco D, et al
High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages.
Antimicrob Agents Chemother. 2025 May 27:e0161324. doi: 10.1128/aac.01613.
PubMed Abstract available

LIU X, Qu X, Zhang R, Zhang Y, et al
Synergistic combination of next-generation polymyxin MRX-8 and meropenem against carbapenem-resistant A. baumannii.
Antimicrob Agents Chemother. 2025 May 27:e0191224. doi: 10.1128/aac.01912.
PubMed Abstract available

XIE L, Li J, Peng Q, Liu X, et al
Contribution of RND superfamily multidrug efflux pumps AdeABC, AdeFGH, and AdeIJK to antimicrobial resistance and virulence factors in multidrug-resistant Acinetobacter baumannii AYE.
Antimicrob Agents Chemother. 2025 May 23:e0185824. doi: 10.1128/aac.01858.
PubMed Abstract available

NELSON ME, Little JL, Kristich CJ
Correction for Nelson et al., "Pbp4 provides transpeptidase activity to the FtsW-PbpB peptidoglycan synthase to drive cephalosporin resistance in Enterococcus faecalis".
Antimicrob Agents Chemother. 2025 May 20:e0059425. doi: 10.1128/aac.00594.
PubMed

HACKEL MA, Karlowsky JA, Sahm DF, West JM, et al
In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus.
Antimicrob Agents Chemother. 2025 May 15:e0029625. doi: 10.1128/aac.00296.
PubMed Abstract available

ZEGANS ME, Kamath MM, Jones JT, Bao R, et al
Propranolol is efficacious against Aspergillus and Fusarium corneal isolates in vitro and in a murine model of Aspergillus keratitis.
Antimicrob Agents Chemother. 2025 May 15:e0166424. doi: 10.1128/aac.01664.
PubMed Abstract available

CEBALLOS-GARZON A, Lebrat J, Holzapfel M, Josa DF, et al
Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains.
Antimicrob Agents Chemother. 2025 May 15:e0013725. doi: 10.1128/aac.00137.
PubMed Abstract available

LI X, Zhou L, Wang D, Wu Q, et al
Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria.
Antimicrob Agents Chemother. 2025;69:e0004425.
PubMed Abstract available

AUBRY R, Buyck JM, Chauzy A, Prouvensier L, et al
PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate.
Antimicrob Agents Chemother. 2025;69:e0179724.
PubMed Abstract available

FLEMING D, Al-Jabri MY, Patel R
Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model.
Antimicrob Agents Chemother. 2025;69:e0172424.
PubMed Abstract available

SAHA S, RoyChowdhury D, Khan AH, Mandal S, et al
Harnessing the effect of iron deprivation to attenuate the growth of opportunistic pathogen Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025;69:e0168924.
PubMed Abstract available

GEBREMARIAM T, Gu Y, Patterson H, Youssef E, et al
Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis.
Antimicrob Agents Chemother. 2025;69:e0180224.
PubMed Abstract available

TIAN X, Jiang T, Dong L, Zhang X, et al
Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections.
Antimicrob Agents Chemother. 2025;69:e0129924.
PubMed Abstract available

SINGH S, Yotsu R, Nuremberger E, Srivastava S, et al
Repurposing drugs to advance the treatment of Buruli ulcer.
Antimicrob Agents Chemother. 2025;69:e0002925.
PubMed Abstract available

LACROIX M, Moreau J, Zampaloni C, Bissantz C, et al
In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025;69:e0153524.
PubMed Abstract available

BADRANE H, Nguyen MH, Clancy CJ
Regulation of phosphatidylinositol-(4,5)-bisphosphate and active-Rho1p levels and distribution is crucial for correct spatio-temporal cytokinesis and echinocandin responses in Candida albicans.
Antimicrob Agents Chemother. 2025 May 5:e0190024. doi: 10.1128/aac.01900.
PubMed Abstract available

April 2025

SONI H, Tyagi S, Mane K, Shelke AM, et al
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 23:e0013025. doi: 10.1128/aac.00130.
PubMed Abstract available

LEE J, Lee I, Lee K-B, Lee SS, et al
Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025 Apr 23:e0188024. doi: 10.1128/aac.01880.
PubMed Abstract available

ZHANG Y, Zhou B, Kong J, Hu P, et al
Prevalence and characteristics of tigecycline- and carbapenem-resistant adeN-truncated Acinetobacter baumannii: a genomic epidemiological analysis.
Antimicrob Agents Chemother. 2025 Apr 23:e0184324. doi: 10.1128/aac.01843.
PubMed Abstract available

LI D, Li L, Zhang Y, Cheng K, et al
Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 22:e0001925. doi: 10.1128/aac.00019.
PubMed Abstract available

SZEL V, Phelan JE, Georghiou SB, Dolinger DL, et al
The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 22:e0026525. doi: 10.1128/aac.00265.
PubMed Abstract available

GOVEL JC, Seabury RW, Asiago-Reddy EA, Gutierrez RL, et al
Evaluation of shorter versus longer antifungal treatment durations for Candida spp. urinary tract infections among hospitalized adults.
Antimicrob Agents Chemother. 2025 Apr 22:e0192024. doi: 10.1128/aac.01920.
PubMed Abstract available

FUTAMURA Y, Yamamoto K, Uson-Lopez R, Aono H, et al
Inhibitory effect of copper chelators on the budding in Candida albicans.
Antimicrob Agents Chemother. 2025 Apr 9:e0003325. doi: 10.1128/aac.00033.
PubMed Abstract available

ARDIZZONI E, Mulders W, De Diego Fuertes M, Hayrapetyan A, et al
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.
Antimicrob Agents Chemother. 2025 Apr 9:e0183924. doi: 10.1128/aac.01839.
PubMed Abstract available

HUANG H, Chen Y, Zhang L, Wan P, et al
Identification and characterization of a novel major facilitator superfamily (MFS) efflux pump conferring multidrug resistance in Staphylococcus aureus and Staphylococcus epidermidis.
Antimicrob Agents Chemother. 2025 Apr 7:e0173924. doi: 10.1128/aac.01739.
PubMed Abstract available

HA KP, Kumeko EK, Bouloc P
A small regulatory RNA controls antibiotic adaptation in Staphylococcus aureus by modulating efflux pump expression.
Antimicrob Agents Chemother. 2025 Apr 3:e0117624. doi: 10.1128/aac.01176.
PubMed Abstract available

HUANG Y, Chiaraviglio L, Bode-Sojobi I, Kirby JE, et al
Triple antimicrobial combinations with potent synergistic activity against M. abscessus.
Antimicrob Agents Chemother. 2025;69:e0182824.
PubMed Abstract available

RIMAL B, Howe RA, Panthi C, Lamichhane G, et al
The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronic Mycobacterium avium lung infection.
Antimicrob Agents Chemother. 2025;69:e0185324.
PubMed Abstract available

SASTRE-FEMENIA MA, Gomis-Font MA, Oliver A
Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel beta-lactams in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2025;69:e0194224.
PubMed Abstract available

SADER HS, Castanheira M, Arends SJR, Doyle TB, et al
Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019-2023).
Antimicrob Agents Chemother. 2025;69:e0012425.
PubMed Abstract available

VEERARAGHAVAN B, Shin E, Bakthavatchalam YD, Manesh A, et al
A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp.
Antimicrob Agents Chemother. 2025;69:e0162724.
PubMed Abstract available

SAMPER-CATIVIELA C, Torre-Fuentes L, Dieguez-Roda B, Maex M, et al
Molecular epidemiology of Salmonella Enteritidis in humans and animals in Spain.
Antimicrob Agents Chemother. 2025;69:e0073824.
PubMed Abstract available

WOLFE TM, Jo J, Pinkham NV, Garey KW, et al
The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice.
Antimicrob Agents Chemother. 2025;69:e0160424.
PubMed Abstract available

MCPHERSON JK, Hurdle JG, Baker ML, Hussain T, et al
The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae.
Antimicrob Agents Chemother. 2025;69:e0167924.
PubMed Abstract available

SAWE S, Tsirizani L, Court R, Gausi K, et al
The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
PubMed Abstract available

March 2025

PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.
Antimicrob Agents Chemother. 2025 Mar 26:e0190124. doi: 10.1128/aac.01901.
PubMed Abstract available

HUANG H, Wan P, Chen Y, Luo X, et al
Phenotypic and genetic stepwise changes in Staphylococcus aureus during in vitro adaptive laboratory evolution under the selective pressure of tigecycline.
Antimicrob Agents Chemother. 2025 Mar 26:e0007225. doi: 10.1128/aac.00072.
PubMed Abstract available

KIM M-J, Zarnowski R, Jones R, Nett JE, et al
Vesicle inhibition reduces Candida biofilm resistance.
Antimicrob Agents Chemother. 2025 Mar 26:e0004525. doi: 10.1128/aac.00045.
PubMed Abstract available

MAHE A, Verneuil N, Coupri D, Hartke A, et al
D-alanylation of lipoteichoic acids inhibitor provides anti-virulence and anti-resistance effects against methicillin-resistant Staphylococcus epidermidis.
Antimicrob Agents Chemother. 2025 Mar 21:e0182224. doi: 10.1128/aac.01822.
PubMed Abstract available

PETERSEN ME, Khamas AB, Ostergaard LJ, Jorgensen NP, et al
Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus.
Antimicrob Agents Chemother. 2025 Mar 14:e0148324. doi: 10.1128/aac.01483.
PubMed Abstract available

MUNITA JM, Tamma PD
Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?
Antimicrob Agents Chemother. 2025 Mar 14:e0012125. doi: 10.1128/aac.00121.
PubMed Abstract available

YU Z, Hu H, Liu X, Liu J, et al
Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study.
Antimicrob Agents Chemother. 2025 Mar 6:e0185924. doi: 10.1128/aac.01859.
PubMed Abstract available

MACK AR, Hujer AM, Mojica MF, Taracila MA, et al
beta-Lactamase diversity in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2025;69:e0078424.
PubMed Abstract available

MACK AR, Hujer AM, Mojica MF, Taracila MA, et al
beta-Lactamase diversity in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2025;69:e0078524.
PubMed Abstract available

RIGATOU A, Afolayan AO, Tatsi E-B, Deliolanis I, et al
Double carbapenemases in Klebsiella pneumoniae blood isolates: dissemination in a single medical center via multiple plasmids and a variety of highly efficient clones.
Antimicrob Agents Chemother. 2025;69:e0146224.
PubMed Abstract available

LEMAITRE N, Dewitte A, Rakotomanimana F, Gooden D, et al
Assessing the threat of Yersinia pestis harboring a multi-resistant IncC plasmid and the efficacy of an antibiotic targeting LpxC.
Antimicrob Agents Chemother. 2025;69:e0149724.
PubMed Abstract available

ROJAS LJ, Nielsen TB, Pantapalangkoor P, Taracila MA, et al
Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030.
Antimicrob Agents Chemother. 2025;69:e0096424.
PubMed Abstract available

DORAZIO AJ, Kline EG, Squires KM, Pogue JM, et al
Restoring ceftolozane susceptibility: a role for diazabicyclooctane beta-lactamase inhibitors?
Antimicrob Agents Chemother. 2025;69:e0154324.
PubMed Abstract available

HAREZA DA, Bergman Y, Jacobs E, Lu J, et al
Molecular epidemiology of beta-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.
Antimicrob Agents Chemother. 2025;69:e0125824.
PubMed Abstract available

MONSIBAIS AN, Tea O, Ghatbale P, Dunham SJB, et al
Enhanced suppression of Stenotrophomonas maltophilia by a three-phage cocktail: genomic insights and kinetic profiling.
Antimicrob Agents Chemother. 2025;69:e0116224.
PubMed Abstract available

CORNISTEIN W, Balasini C, Nuccetelli Y, Rodriguez VM, et al
Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR).
Antimicrob Agents Chemother. 2025;69:e0142624.
PubMed Abstract available

VEVE MP, Kenney RM, Aljundi AM, Dierker MS, et al
Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.
Antimicrob Agents Chemother. 2025 Mar 4:e0159624. doi: 10.1128/aac.01596.
PubMed Abstract available

February 2025

YU H, Wang L, Liu X, Zheng J, et al
Mechanistic insights into the multitarget synergistic efficacy of farrerol and beta-lactam antibiotics in combating methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2025 Feb 28:e0155124. doi: 10.1128/aac.01551.
PubMed Abstract available

FU S-Y, Chen X-Z, Yi P-C, Gao J, et al
Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing.
Antimicrob Agents Chemother. 2025 Feb 26:e0168324. doi: 10.1128/aac.01683.
PubMed Abstract available

COJUTTI PG, Gatti M, Tedeschi S, Zamparini E, et al
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.
Antimicrob Agents Chemother. 2025 Feb 24:e0183024. doi: 10.1128/aac.01830.
PubMed Abstract available

FILE TM JR, Ramirez JA, Wilde AM
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).
Antimicrob Agents Chemother. 2025;69:e0108724.
PubMed Abstract available

BONCOMPAGNI SR, Riccobono E, Cusi MG, Di Pilato V, et al
Evidence of dissemination of a clc-type integrative and conjugative element to Stenotrophomonas maltophilia, mediating acquisition of sul1 and other resistance determinants.
Antimicrob Agents Chemother. 2025;69:e0155424.
PubMed Abstract available

TONG DMH, Hughes M-SA, Hu J, Pearson JC, et al
Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis.
Antimicrob Agents Chemother. 2025;69:e0104024.
PubMed Abstract available

CLAEYS KC, Simner PJ, Tekle T, Harris AD, et al
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
Antimicrob Agents Chemother. 2025;69:e0138724.
PubMed Abstract available

SANCHO-SANCHEZ E, Garcia-Arteaga K, Granados-Chinchilla F, Artavia G, et al
Reactivation of hidden-latent Brucella infection after doxycycline and streptomycin treatment in mice.
Antimicrob Agents Chemother. 2025;69:e0130224.
PubMed Abstract available

ROSON-CALERO N, Gomis Font MA, Ruiz-Soriano A, Just-Baringo X, et al
In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide.
Antimicrob Agents Chemother. 2025;69:e0145924.
PubMed Abstract available

SHIN E, Dousa KM, Taracila MA, Bethel CR, et al
Durlobactam in combination with beta-lactams to combat Mycobacterium abscessus.
Antimicrob Agents Chemother. 2025;69:e0117424.
PubMed Abstract available

JU Y, Li L, Zhang J, Yusuf B, et al
The gene MAB_2362 is responsible for intrinsic resistance to various drugs and virulence in Mycobacterium abscessus by regulating cell division.
Antimicrob Agents Chemother. 2025;69:e0043324.
PubMed Abstract available

AMOURA A, Benchetrit L, Magreault S, Chosidow S, et al
Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1.
Antimicrob Agents Chemother. 2025;69:e0128822.
PubMed Abstract available

ABDUL-AZIZ MH, Diehl A, Liu X, Cheng V, et al
Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study.
Antimicrob Agents Chemother. 2025;69:e0143524.
PubMed Abstract available

GHEBREKRISTOS Y, Ahmed A, Beylis N, Singh S, et al
Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
Antimicrob Agents Chemother. 2025 Feb 7:e0167124. doi: 10.1128/aac.01671.
PubMed Abstract available

January 2025

SALADO-RASMUSSEN K, Norgaard C, Pedersen TR, Paukner S, et al
In vitro test of the novel antibiotic lefamulin alone and in combination with doxycycline against Mycoplasma genitalium.
Antimicrob Agents Chemother. 2025;69:e0134624.
PubMed Abstract available

GONG Y, Jiang R, Guo RH, Jo SJ, et al
TolCV1 inhibition by NPPB renders Vibrio vulnificus less virulent and more susceptible to antibiotics.
Antimicrob Agents Chemother. 2025;69:e0050224.
PubMed Abstract available

FORRISTER NM, McCarty TP, Pappas PG
New Perspectives on Antimicrobial Agents: Rezafungin.
Antimicrob Agents Chemother. 2025;69:e0064623.
PubMed Abstract available

LI T, Zhu Y, Xiang G, Xu Z, et al
Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy.
Antimicrob Agents Chemother. 2025;69:e0123524.
PubMed Abstract available

ABOUELHASSAN Y, Shen Y, Chen A, Ye X, et al
Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.
Antimicrob Agents Chemother. 2025;69:e0167423.
PubMed Abstract available

HE Z, Huang Y, Li W, Zhang H, et al
Characterization and genomic analysis of the highly virulent Acinetobacter baumannii ST1791 strain dominating in Anhui, China.
Antimicrob Agents Chemother. 2025;69:e0126224.
PubMed Abstract available

QUESILLE-VILLALOBOS AM, Solar C, Martinez JRW, Rivas L, et al
Multispecies emergence of dual bla(KPC/NDM) carbapenemase-producing Enterobacterales recovered from invasive infections in Chile.
Antimicrob Agents Chemother. 2025;69:e0120524.
PubMed Abstract available

MORITA D, Mukhopadhyay AK, Chowdhury G, Maruyama F, et al
Genomic epidemiology and genetic characteristics of clinical Campylobacter species cocirculating in West Bengal, India, 2019, using whole genome analysis.
Antimicrob Agents Chemother. 2025;69:e0110824.
PubMed Abstract available

WIEDERHOLD NP, Patterson HP, Ferrer D, Garcia V, et al
Olorofim demonstrates in vitro activity against Coccidioides species, including isolates against which fluconazole has reduced activity.
Antimicrob Agents Chemother. 2025;69:e0098824.
PubMed Abstract available

NEGATU DA, Aragaw WW, Gebresilase TT, Paruchuri S, et al
Durlobactam to boost the clinical utility of standard of care beta-lactams against Mycobacterium abscessus lung disease.
Antimicrob Agents Chemother. 2025;69:e0104624.
PubMed Abstract available

GAO L, Wu H, Feng J, Liu Y, et al
In vitro and in vivo activity of 1,2,3,4,6-O-pentagalloyl-glucose against Candida albicans.
Antimicrob Agents Chemother. 2025 Jan 24:e0177524. doi: 10.1128/aac.01775.
PubMed Abstract available

ZHU Q, Wijnants S, Feil R, Van Genechten W, et al
The stress-protectant molecule trehalose mediates fluconazole tolerance in Candida glabrata.
Antimicrob Agents Chemother. 2025 Jan 24:e0134924. doi: 10.1128/aac.01349.
PubMed Abstract available

WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice.
Antimicrob Agents Chemother. 2025 Jan 17:e0131024. doi: 10.1128/aac.01310.
PubMed Abstract available

VOGENSEN VB, Singh S, Allende CJ, Engelthaler DM, et al
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
Antimicrob Agents Chemother. 2025 Jan 16:e0108424. doi: 10.1128/aac.01084.
PubMed Abstract available

SADER HS, Smart JI, Mendes RE, Castanheira M, et al
Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022.
Antimicrob Agents Chemother. 2025 Jan 13:e0140224. doi: 10.1128/aac.01402.
PubMed Abstract available

December 2024

JEHANNE Q, Benejat L, Ducournau A, Aptel J, et al
Increasing rates of erm(B) and erm(N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France.
Antimicrob Agents Chemother. 2024 Dec 31:e0166824. doi: 10.1128/aac.01668.
PubMed Abstract available

NDZAMBA B, Denti P, McIlleron H, Smith P, et al
Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
PubMed Abstract available

OLLINGER TL, Zarnowski R, Parker JE, Kelly SL, et al
Genetic interaction analysis of Candida glabrata transcription factors CST6 and UPC2A in the regulation of respiration and fluconazole susceptibility.
Antimicrob Agents Chemother. 2024 Dec 23:e0129424. doi: 10.1128/aac.01294.
PubMed Abstract available

ZAGALIOTIS P, Michalik-Provasek J, Mavridou E, Naing E, et al
Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection.
Antimicrob Agents Chemother. 2024 Dec 20:e0091924. doi: 10.1128/aac.00919.
PubMed Abstract available

GHATBALE P, Sah GP, Dunham S, Khong E, et al
In vitro resensitization of multidrug-resistant clinical isolates of Enterococcus faecium and E. faecalis through phage-antibiotic synergy.
Antimicrob Agents Chemother. 2024 Dec 19:e0074024. doi: 10.1128/aac.00740.
PubMed Abstract available

MANSJO M, Espinosa-Gongora C, Samanci I, Groenheit R, et al
Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the Mycobacterium tuberculosis complex based on the EUCAST reference protocol.
Antimicrob Agents Chemother. 2024 Dec 18:e0094624. doi: 10.1128/aac.00946.
PubMed Abstract available

HIRAYAMA T, Miyazaki T, Tanaka R, Kitahori N, et al
TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression.
Antimicrob Agents Chemother. 2024 Dec 18:e0150824. doi: 10.1128/aac.01508.
PubMed Abstract available

HEINE HS, Purcell BK, Duncan C, Miller L, et al
Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant Burkholderia pseudomallei in a murine infection model.
Antimicrob Agents Chemother. 2024 Dec 13:e0129524. doi: 10.1128/aac.01295.
PubMed Abstract available

LEE S, Park S, Kim JN, Lee SO, et al
Polymorphisms in the type A blaZ gene as determinants of the cefazolin inoculum effect in Staphylococcus aureus.
Antimicrob Agents Chemother. 2024 Dec 10:e0110624. doi: 10.1128/aac.01106.
PubMed Abstract available

KOMM OD, Tyagi S, Garcia A, Almeida D, et al
Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962.
PubMed Abstract available

BLANCO-MARTIN T, Gonzalez-Pinto L, Aja-Macaya P, Rodriguez-Pallares S, et al
Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.
Antimicrob Agents Chemother. 2024;68:e0112024.
PubMed Abstract available

SEGERS H, Deville JG, Muller WJ, Manzanares A, et al
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
Antimicrob Agents Chemother. 2024;68:e0048424.
PubMed Abstract available

HANSSEN JLJ, van der Wal RJP, Mahdad R, Keizer S, et al
Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: a prospective multicenter study.
Antimicrob Agents Chemother. 2024;68:e0123224.
PubMed Abstract available

LE TM, Eubank TA, McKelvey AM, Cao X, et al
Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.
Antimicrob Agents Chemother. 2024;68:e0120624.
PubMed Abstract available

ZHAO H, Hu Y, Nie D, Li N, et al
A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity.
Antimicrob Agents Chemother. 2024;68:e0056524.
PubMed Abstract available

WU J, Chen C, Luo C, Ning B, et al
Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients.
Antimicrob Agents Chemother. 2024;68:e0111224.
PubMed Abstract available

RODRIGUEZ-PALLARES S, Blanco-Martin T, Lence E, Aja-Macaya P, et al
In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC beta-lactamase in Klebsiella aerogenes.
Antimicrob Agents Chemother. 2024;68:e0130724.
PubMed Abstract available

BALDRY M, Costa C, Zeroual Y, Cayet D, et al
Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia.
Antimicrob Agents Chemother. 2024;68:e0086624.
PubMed Abstract available

JACOBS MR, Good CE, Abdelhamed AM, Mack AR, et al
ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate beta-lactamase inhibitor ledaborbactam combined with ceftibuten.
Antimicrob Agents Chemother. 2024;68:e0112724.
PubMed Abstract available

FAN J, Tan Z, He S, Li A, et al
TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2024;68:e0094524.
PubMed Abstract available

XU T, Wu W, Huang L, Liu B, et al
Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli.
Antimicrob Agents Chemother. 2024;68:e0090624.
PubMed Abstract available

ZO S, Choe J, Kim DH, Kim S-Y, et al
Long-term clinical course of Mycobacterium avium complex pulmonary disease patients with treatment failure.
Antimicrob Agents Chemother. 2024;68:e0105524.
PubMed Abstract available

WANG L, Li Y, Xiu L, Hu L, et al
Multigeographic clinical assessment of a molecular diagnostic assay for detection of key codons to predict decreased susceptibility or resistance to cephalosporins in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2024;68:e0116524.
PubMed Abstract available

MOLASKY NMR, Zhang Z, Gillespie JR, Domagala J, et al
A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.
Antimicrob Agents Chemother. 2024;68:e0074524.
PubMed Abstract available

MELENDEZ JH, Edwards VL, Muniz Tirado A, Hardick J, et al
Local emergence and global evolution of Neisseria gonorrhoeae with high-level resistance to azithromycin.
Antimicrob Agents Chemother. 2024;68:e0092724.
PubMed Abstract available

November 2024

VOCAT A, Luraschi-Eggemann A, Antoni C, Cathomen G, et al
Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis.
Antimicrob Agents Chemother. 2024 Nov 27:e0131824. doi: 10.1128/aac.01318.
PubMed Abstract available

JIA H, Li X, Zhuang Y, Wu Y, et al
Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant Acinetobacter baumannii from whole genome sequencing and gene expression.
Antimicrob Agents Chemother. 2024 Nov 14:e0144624. doi: 10.1128/aac.01446.
PubMed Abstract available

VEGA LA, Sanson-Iglesias M, Mukherjee P, Buchan KD, et al
LiaR-dependent gene expression contributes to antimicrobial responses in group A Streptococcus.
Antimicrob Agents Chemother. 2024 Nov 13:e0049624. doi: 10.1128/aac.00496.
PubMed Abstract available

HERRERA C, Gomis-Font MA, Lopez-Causape C, Diez-Aguilar M, et al
Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.
Antimicrob Agents Chemother. 2024;68:e0116424.
PubMed Abstract available

SATTLER J, Ernst CM, Zweigner J, Hamprecht A, et al
High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013-2021.
Antimicrob Agents Chemother. 2024;68:e0060224.
PubMed Abstract available

RIMAL B, Howe RA, Panthi CM, Wang W, et al
Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse.
Antimicrob Agents Chemother. 2024;68:e0135124.
PubMed Abstract available

RODVOLD KA, Gotfried MH, Ussery XT, Wong SL, et al
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.
Antimicrob Agents Chemother. 2024;68:e0110324.
PubMed Abstract available

PUUMALA E, Nabeela S, Thornburg CC, Grkovic T, et al
Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy.
Antimicrob Agents Chemother. 2024;68:e0119424.
PubMed Abstract available

SEREME Y, Faury H, Gravrand V, Ageron E, et al
Molecular insights into the evolutionary trajectory of a Klebsiella aerogenes clinical isolate with a complex trade-off between resistance and virulence.
Antimicrob Agents Chemother. 2024;68:e0103624.
PubMed Abstract available

MARTIN MJ, Luo TL, Kovalchuk V, Kondratiuk V, et al
Detection of cefiderocol and aztreonam/avibactam resistance in epidemic Escherichia coli ST-361 carrying bla(NDM-5) and bla(KPC-3) from foreign fighters evacuated from Ukraine.
Antimicrob Agents Chemother. 2024;68:e0109024.
PubMed Abstract available

OKE MT, Martz K, Mocanita M, Knezevic S, et al
Analysis of Acinetobacter P-type type IV secretion system-encoding plasmid diversity uncovers extensive secretion system conservation and diverse antibiotic resistance determinants.
Antimicrob Agents Chemother. 2024 Nov 4:e0103824. doi: 10.1128/aac.01038.
PubMed Abstract available

October 2024

LI J, Brandalise D, Coste AT, Sanglard D, et al
Exploration of novel mechanisms of azole resistance in Candida auris.
Antimicrob Agents Chemother. 2024 Oct 31:e0126524. doi: 10.1128/aac.01265.
PubMed Abstract available

KON H, Lurie-Weinberger MN, Bechor M, Temkin E, et al
bla(GES)-producing ST654 comprises a quarter of all carbapenem-resistant Pseudomonas aeruginosa in blood isolates from 15 hospitals.
Antimicrob Agents Chemother. 2024 Oct 31:e0096524. doi: 10.1128/aac.00965.
PubMed Abstract available

LEPAK AJ, Massey J, Zarnowski R, Olesen TK, et al
In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models.
Antimicrob Agents Chemother. 2024 Oct 29:e0123424. doi: 10.1128/aac.01234.
PubMed Abstract available

SNOBRE J, Meehan CJ, Mulders W, Rigouts L, et al
Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Oct 24:e0085424. doi: 10.1128/aac.00854.
PubMed Abstract available

MA Z, Zeng W, Liu H, Chen H, et al
Characterization of novel sequence type 12531 and O8:H7 serotype carbapenem-resistant Escherichia coli with strong swimming and intestinal epithelial cell barrier migration abilities.
Antimicrob Agents Chemother. 2024 Oct 23:e0080524. doi: 10.1128/aac.00805.
PubMed Abstract available

LEDGER EVK, Massey RC
PBP4 is required for serum-induced cell wall thickening and antibiotic tolerance in Staphylococcus aureus.
Antimicrob Agents Chemother. 2024 Oct 21:e0096124. doi: 10.1128/aac.00961.
PubMed Abstract available

MAITRE T, Godmer A, Mory C, Chauffour A, et al
Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis.
Antimicrob Agents Chemother. 2024 Oct 16:e0058324. doi: 10.1128/aac.00583.
PubMed Abstract available

STORER ISR, Sastre-Velasquez LE, Easter T, Mertens B, et al
Shining a light on the impact of antifungals on Aspergillus fumigatus subcellular dynamics through fluorescence imaging.
Antimicrob Agents Chemother. 2024 Oct 15:e0080324. doi: 10.1128/aac.00803.
PubMed Abstract available

KENT AG, Spicer LM, Campbell D, Breaker E, et al
Sentinel Surveillance reveals phylogenetic diversity and detection of linear plasmids harboring vanA and optrA among enterococci collected in the United States.
Antimicrob Agents Chemother. 2024 Oct 15:e0059124. doi: 10.1128/aac.00591.
PubMed Abstract available

ZARSKE M, Werckenthin C, Golz JC, Stingl K, et al
The point mutation A1387G in the 16S rRNA gene confers aminoglycoside resistance in Campylobacter jejuni and Campylobacter coli.
Antimicrob Agents Chemother. 2024 Oct 15:e0083324. doi: 10.1128/aac.00833.
PubMed Abstract available

SALAMA EA, Elgammal Y, Utturkar SM, Lanman NA, et al
Overcoming amphotericin B resistance in Candida auris using the antiemetic drug rolapitant.
Antimicrob Agents Chemother. 2024 Oct 10:e0055624. doi: 10.1128/aac.00556.
PubMed Abstract available

HONG H, Fan L, Shi W, Zhu Y, et al
Overexpression of beta-lactamase genes (bla(KPC,) bla(SHV)) and novel CirA deficiencies contribute to decreased cefiderocol susceptibility in carbapenem-resistant Klebsiella pneumoniae before its approval in China.
Antimicrob Agents Chemother. 2024 Oct 10:e0075424. doi: 10.1128/aac.00754.
PubMed Abstract available

BOAST A, Zhang W, Soeorg H, Gonis G, et al
Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?
Antimicrob Agents Chemother. 2024 Oct 8:e0074724. doi: 10.1128/aac.00747.
PubMed Abstract available

HENRIKSEN NL, Serrano-Chavez E, Fuglsang-Madsen A, Jensen LK, et al
Gentamicin and clindamycin antibiotic-eluting depot technology eradicates S. aureus in an implant-associated osteomyelitis pig model without systemic antibiotics.
Antimicrob Agents Chemother. 2024;68:e0069124.
PubMed Abstract available

GOH JJN, Wang Q, Zhang N, de Castro Suarez N, et al
Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
Antimicrob Agents Chemother. 2024;68:e0061524.
PubMed Abstract available

KAUR JN, Klem JF, Liu Y, Boissonneault KR, et al
Maximally precise combinations to overcome metallo-beta-lactamase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2024;68:e0077024.
PubMed Abstract available

NUMATA S, Hara T, Izawa M, Okuno Y, et al
Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.
Antimicrob Agents Chemother. 2024;68:e0069424.
PubMed Abstract available

LI H, Oliver A, Shields RK, Kamat S, et al
Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021.
Antimicrob Agents Chemother. 2024;68:e0067024.
PubMed Abstract available

STURARO MC, Damaceno NdS, Faccin ID, Silva ON, et al
Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis.
Antimicrob Agents Chemother. 2024;68:e0093024.
PubMed Abstract available

PLUMET L, Costechareyre D, Lavigne J-P, Kissa K, et al
Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.
Antimicrob Agents Chemother. 2024;68:e0082924.
PubMed Abstract available

HUANG H, Yang H, Feng S, Zhang X, et al
High salt condition alters LPS synthesis and induces the emergence of drug resistance mutations in Helicobacter pylori.
Antimicrob Agents Chemother. 2024;68:e0058724.
PubMed Abstract available

RUBIO J, Yan J, Miller S, Cheng J, et al
Polymyxins retain in vitro activity and in vivo efficacy against "resistant" Acinetobacter baumannii strains when tested in physiological conditions.
Antimicrob Agents Chemother. 2024;68:e0072524.
PubMed Abstract available

SINGH V, Nandanwar H
IMT-P8 potentiates Gram-positive specific antibiotics in intrinsically resistant Gram-negative bacteria.
Antimicrob Agents Chemother. 2024;68:e0075324.
PubMed Abstract available

HAREZA DA, Cosgrove SE, Bonomo RA, Dzintars K, et al
Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
Antimicrob Agents Chemother. 2024;68:e0090724.
PubMed Abstract available

WOOD GE, Lee JW, Peramuna T, Wendt KL, et al
The fungal natural product fusidic acid demonstrates potent activity against Mycoplasma genitalium.
Antimicrob Agents Chemother. 2024;68:e0100624.
PubMed Abstract available

ZELMER AR, Yang D, Gunn NJ, Solomon LB, et al
Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes.
Antimicrob Agents Chemother. 2024;68:e0080824.
PubMed Abstract available

GAONA M, Corral J, Campoy S, Barbe J, et al
The novel MFS efflux pump SxtP, regulated by the LysR-type transcriptional activator SxtR, is involved in the susceptibility to sulfamethoxazole/trimethoprim (SXT) and the pathogenesis of Acinetobacter baumannii.
Antimicrob Agents Chemother. 2024;68:e0071224.
PubMed Abstract available

ALLAIN M, Morel-Journel T, Condamine B, Gibeaux B, et al
IncC plasmid genome rearrangements influence the vertical and horizontal transmission tradeoff in Escherichia coli.
Antimicrob Agents Chemother. 2024;68:e0055424.
PubMed Abstract available

DUBEY V, Farrington N, Harper N, Johnson A, et al
Acinetobacter baumannii transformants expressing oxacillinases and metallo-beta-lactamases that confer resistance to meropenem: new tools for anti-Acinetobacter drug development and AMR preparedness.
Antimicrob Agents Chemother. 2024;68:e0022224.
PubMed Abstract available

XU J-Y, Dong H-h, Liao L-j, Yang S-x, et al
Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment.
Antimicrob Agents Chemother. 2024;68:e0095924.
PubMed Abstract available

SINTES R, McLellan P, Navelli G, Landman C, et al
Use of frozen native feces for fecal microbiota transplantation in recurrent Clostridioides difficile infection: a simple way to improve the efficiency of donor feces preparation.
Antimicrob Agents Chemother. 2024;68:e0073424.
PubMed Abstract available

YASMIN M, Marshall SH, Chen L, Rhoads DD, et al
A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2024;68:e0020824.
PubMed Abstract available

TAVAKKOL A, DuBois JC, Gupta AK
Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis.
Antimicrob Agents Chemother. 2024;68:e0068224.
PubMed Abstract available

RENDON MA, So M
Zap the clap with DNA: a novel microbicide for preventing Neisseria gonorrhoeae infection.
Antimicrob Agents Chemother. 2024;68:e0079424.
PubMed Abstract available

FUKUSHIMA K, Matsumoto Y, Abe Y, Hashimoto K, et al
Variability of macrolide-resistant profile in Mycobacterium avium complex pulmonary disease.
Antimicrob Agents Chemother. 2024 Oct 8:e0121324. doi: 10.1128/aac.01213.
PubMed Abstract available

GUIN S, Montoya MC, Wang X, Zarnowski R, et al
Analogs of the anti-malaria drug mefloquine have broad-spectrum antifungal activity and are efficacious in a model of disseminated Candida auris infection.
Antimicrob Agents Chemother. 2024 Oct 4:e0130124. doi: 10.1128/aac.01301.
PubMed Abstract available

September 2024

ENCINAS L, Li S-Y, Rullas-Trincado J, Tasneen R, et al
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 30:e0035724. doi: 10.1128/aac.00357.
PubMed Abstract available

CARVAJAL LP, Rincon S, Gomez Villegas SI, Matiz-Gonzalez JM, et al
Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection.
Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898.
PubMed Abstract available

BAUMAN AA, Sarathy JP, Kaya F, Massoudi LM, et al
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 30:e0071624. doi: 10.1128/aac.00716.
PubMed Abstract available

WASIELEWSKI AS, Casapao AM, Jankowski CA, Isache CL, et al
Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.
Antimicrob Agents Chemother. 2024 Sep 26:e0075224. doi: 10.1128/aac.00752.
PubMed Abstract available

MATUSIK E, Vassal O, Conrad A, Ferry T, et al
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections.
Antimicrob Agents Chemother. 2024 Sep 26:e0099124. doi: 10.1128/aac.00991.
PubMed Abstract available

ALLEN R, Ames L, Baldin VP, Butts A, et al
An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 26:e0103724. doi: 10.1128/aac.01037.
PubMed Abstract available

POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis".
Antimicrob Agents Chemother. 2024 Sep 19:e0135424. doi: 10.1128/aac.01354.
PubMed

RHODES J, Jacobs J, Dennis EK, Manjari SR, et al
What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs.
Antimicrob Agents Chemother. 2024 Sep 19:e0091124. doi: 10.1128/aac.00911.
PubMed Abstract available

CASTANHEIRA M, Deshpande LM, Rhomberg PR, Carvalhaes CG, et al
Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization.
Antimicrob Agents Chemother. 2024 Sep 12:e0057024. doi: 10.1128/aac.00570.
PubMed Abstract available

LE RUN E, Tettelin H, Holland SM, Zelazny AM, et al
Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains.
Antimicrob Agents Chemother. 2024 Sep 10:e0067324. doi: 10.1128/aac.00673.
PubMed Abstract available

KOMORI K, Aoki K, Harada S, Ishii Y, et al
Plasmid-mediated acquisition and chromosomal integration of bla(CTX-M-14) in a subclade of Escherichia coli ST131-H30 clade C1.
Antimicrob Agents Chemother. 2024;68:e0081724.
PubMed Abstract available

BHAVNANI SM, Hammel JP, Lakota EA, Liolios K, et al
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother. 2024;68:e0128123.
PubMed Abstract available

LIU L, Wang L, Liu X, Wang B, et al
Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence.
Antimicrob Agents Chemother. 2024;68:e0061124.
PubMed Abstract available

August 2024

MARTINI MC, Alonso MN, Cafiero JH, Xiao J, et al
Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Aug 28:e0064524. doi: 10.1128/aac.00645.
PubMed Abstract available

TIAN P, Li Q-Q, Guo M-J, Zhu Y-Z, et al
Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2024 Aug 28:e0034424. doi: 10.1128/aac.00344.
PubMed Abstract available

MOLENDIJK MM, Boekema BKHL, Lattwein KR, Vlig M, et al
Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model.
Antimicrob Agents Chemother. 2024 Aug 13:e0065024. doi: 10.1128/aac.00650.
PubMed Abstract available

ROTONDO CM, Wright GD
Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple beta-lactamases.
Antimicrob Agents Chemother. 2024 Aug 12:e0027224. doi: 10.1128/aac.00272.
PubMed Abstract available

HEINE HS, Drusano G, Purcell BK, Anastasiou D, et al
Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis.
Antimicrob Agents Chemother. 2024 Aug 12:e0059524. doi: 10.1128/aac.00595.
PubMed Abstract available

EISHA S, Morris AJ, Martin I, Yau YCW, et al
Effect of L-arginine on cystic fibrosis Pseudomonas aeruginosa biofilms.
Antimicrob Agents Chemother. 2024;68:e0033624.
PubMed Abstract available

RIMAL B, Lippincott CK, Panthi CM, Xie Y, et al
Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection.
Antimicrob Agents Chemother. 2024;68:e0064824.
PubMed Abstract available

EGGE SL, Rizvi SA, Simar SR, Alcalde M, et al
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin.
Antimicrob Agents Chemother. 2024;68:e0012724.
PubMed Abstract available

PONTA G, Morena V, Strano M, Molteni C, et al
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).
Antimicrob Agents Chemother. 2024;68:e0075024.
PubMed Abstract available

SUN Y, Zhang K, Delos Santos M, Pee CJE, et al
An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection.
Antimicrob Agents Chemother. 2024;68:e0152023.
PubMed Abstract available

WIECZORKIEWICZ JT, Skinner AM, Cheknis A, Petrella LA, et al
Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.
Antimicrob Agents Chemother. 2024;68:e0069824.
PubMed Abstract available

July 2024

NELSON ME, Little JL, Kristich CJ
Pbp4 provides transpeptidase activity to the FtsW-PbpB peptidoglycan synthase to drive cephalosporin resistance in Enterococcus faecalis.
Antimicrob Agents Chemother. 2024 Jul 26:e0055524. doi: 10.1128/aac.00555.
PubMed Abstract available

ADELMAN MW, Andes DR
Case Commentary: Extending our therapeutic range against multidrug-resistant Candida.
Antimicrob Agents Chemother. 2024 Jul 22:e0084724. doi: 10.1128/aac.00847.
PubMed Abstract available

ROBERTS AH, Moon CW, Faulkner V, Kendall SL, et al
EfpA is required for regrowth of Mycobacterium tuberculosis following isoniazid exposure.
Antimicrob Agents Chemother. 2024 Jul 22:e0026124. doi: 10.1128/aac.00261.
PubMed Abstract available

WASSERMAN S, Antilus-Sainte R, Abdelgawad N, Odjourian NM, et al
Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
Antimicrob Agents Chemother. 2024 Jul 19:e0078324. doi: 10.1128/aac.00783.
PubMed Abstract available

TRUONG-BOLDUC QC, Wang Y, Lawton BG, Brown Harding H, et al
Phenazine-1 carboxylic acid of Pseudomonas aeruginosa induces the expression of Staphylococcus aureus Tet38 MDR efflux pump and mediates resistance to phenazines and antibiotics.
Antimicrob Agents Chemother. 2024 Jul 19:e0063624. doi: 10.1128/aac.00636.
PubMed Abstract available

SIMEON S, Garcia-Cremades M, Savic R, Solans BP, et al
Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.
Antimicrob Agents Chemother. 2024 Jul 17:e0019024. doi: 10.1128/aac.00190.
PubMed Abstract available

GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
PubMed Abstract available

STRAHILEVITZ J, Motro Y, Temper V, Merezhko D, et al
In vivo selection of carbapenem resistance during persistent Klebsiella pneumoniae sequence type 395 bloodstream infection due to OmpK36 deletion.
Antimicrob Agents Chemother. 2024 Jul 11:e0066324. doi: 10.1128/aac.00663.
PubMed Abstract available

ANTONELLI A, Coppi M, Bonaiuto C, Giovacchini N, et al
Pseudomonas aeruginosa producing FIM-1-metallo-beta-lactamase: emergence and cross-transmission in a long-term acute care rehabilitation hospital.
Antimicrob Agents Chemother. 2024;68:e0057424.
PubMed Abstract available

LAWRENCE WS, Peel JE, Slayden RA, Peterson JW, et al
Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model.
Antimicrob Agents Chemother. 2024;68:e0011224.
PubMed Abstract available

LIPPINCOTT CK, Lamichhane G
Case Commentary: Dual beta-lactam as part of regimen to treat Mycobacterium abscessus lung disease.
Antimicrob Agents Chemother. 2024;68:e0058524.
PubMed Abstract available

CLUTTER DS, Samiezade-Yazd Z, Champsi JH, Schapiro J, et al
Antibiotic duration and route for treatment of adults with uncomplicated streptococcal bloodstream infections: a retrospective study in a large healthcare system.
Antimicrob Agents Chemother. 2024 Jul 8:e0022024. doi: 10.1128/aac.00220.
PubMed Abstract available

BEREDAKI M-I, Arendrup MC, Pournaras S, Meletiadis J, et al
Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Candida species in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2024 Jul 3:e0022524. doi: 10.1128/aac.00225.
PubMed Abstract available

June 2024

KURTZHALS ML, Norman A, Svensson E, Lillebaek T, et al
Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis: leveraging 20 years of nationwide data from Denmark.
Antimicrob Agents Chemother. 2024 Jun 21:e0043024. doi: 10.1128/aac.00430.
PubMed Abstract available

PLUMET L, Magnan C, Ahmad-Mansour N, Sotto A, et al
The zebrafish embryo model: unveiling its potential for investigating phage therapy against methicillin-resistant Staphylococcus aureus infection.
Antimicrob Agents Chemother. 2024 Jun 20:e0056124. doi: 10.1128/aac.00561.
PubMed Abstract available

REIDENBERG BE, Jenkins SG, Crandon JL, Hurlburt E, et al
In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections.
Antimicrob Agents Chemother. 2024 Jun 12:e0038124. doi: 10.1128/aac.00381.
PubMed Abstract available

MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
PubMed Abstract available

PETERSIEL N, Giulieri S, Daniel DS, Fan S-H, et al
Genomic investigation and clinical correlates of the in vitro beta-lactam: NaHCO(3) responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial.
Antimicrob Agents Chemother. 2024 Jun 5:e0021824. doi: 10.1128/aac.00218.
PubMed Abstract available

MINUK LM, Brode SK, Mehrabi M, Sharma MK, et al
Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease.
Antimicrob Agents Chemother. 2024;68:e0008424.
PubMed Abstract available

TANG M, Yao Z, Liu Y, Ma Z, et al
Host immunity involvement in the outcome of phage therapy against hypervirulent Klebsiella pneumoniae infections.
Antimicrob Agents Chemother. 2024;68:e0142923.
PubMed Abstract available

HERREN SC, Karau MJ, Koscianski CA, Christensen TA, et al
Phage K exposure generates phage-neutralizing activity in a rabbit model-humoral receptiveness may impact efficacy of phage therapy.
Antimicrob Agents Chemother. 2024;68:e0005224.
PubMed Abstract available

GU X, Lu H, Yang Y, Zhu L, et al
Could ceftriaxone be a viable alternative to penicillin for the treatment of ocular syphilis?
Antimicrob Agents Chemother. 2024;68:e0008024.
PubMed Abstract available

NEGATU DA, Aragaw WW, Dartois V, Dick T, et al
A pairwise approach to revitalize beta-lactams for the treatment of TB.
Antimicrob Agents Chemother. 2024;68:e0003424.
PubMed Abstract available

GU Y, Gebremariam T, Alkhazraji S, Youssef E, et al
Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.
Antimicrob Agents Chemother. 2024;68:e0154023.
PubMed Abstract available

TONG Q, Yin C, Hang X, Bai Y, et al
Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori.
Antimicrob Agents Chemother. 2024;68:e0031424.
PubMed Abstract available

BROWN-ELLIOTT BA, Bush G, Hughes MD, Rodriguez E, et al
In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM).
Antimicrob Agents Chemother. 2024;68:e0168423.
PubMed Abstract available

BERNARD C, Liu Y, Larrouy-Maumus G, Guilhot C, et al
Altered serine metabolism promotes drug tolerance in Mycobacterium abscessus via a WhiB7-mediated adaptive stress response.
Antimicrob Agents Chemother. 2024;68:e0145623.
PubMed Abstract available

CHUDEJOVA K, Sourenian T, Palkovicova J, Stredanska K, et al
Genomic characterization of ST38 NDM-5-producing Escherichia coli isolates from an outbreak in the Czech Republic.
Antimicrob Agents Chemother. 2024;68:e0013324.
PubMed Abstract available

WALSH KF, Lee MH, Zainabadi K, Vilbrun SC, et al
High variance in quantification of Mycobacterium tuberculosis at low bacterial loads and with differentially detectable mycobacteria.
Antimicrob Agents Chemother. 2024 Jun 3:e0160123. doi: 10.1128/aac.01601.
PubMed Abstract available

May 2024

HUANG E, Thompson RN, Moon SH, Keck JM, et al
Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA.
Antimicrob Agents Chemother. 2024 May 29:e0029024. doi: 10.1128/aac.00290.
PubMed Abstract available

GAVIRAGHI A, de Nicolo A, Venuti F, Stroffolini G, et al
Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?
Antimicrob Agents Chemother. 2024 May 24:e0023424. doi: 10.1128/aac.00234.
PubMed

ANOY MMI, Kim W-J, Gelston S, Fleming D, et al
Evaluation of treatment of methicillin-resistant Staphylococcus aureus biofilms with intermittent electrochemically generated H(2)O(2) or HOCl.
Antimicrob Agents Chemother. 2024 May 21:e0172223. doi: 10.1128/aac.01722.
PubMed Abstract available

BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
PubMed Abstract available

LUO J, Liu M, Ai W, Zheng X, et al
Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2024 May 14:e0044824. doi: 10.1128/aac.00448.
PubMed Abstract available

HULTQVIST LD, Andersen JB, Nilsson CM, Jansen CU, et al
High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin.
Antimicrob Agents Chemother. 2024 May 8:e0148123. doi: 10.1128/aac.01481.
PubMed Abstract available

BERGIN S, Doorley LA, Rybak JM, Wolfe KH, et al
Analysis of clinical Candida parapsilosis isolates reveals copy number variation in key fluconazole resistance genes.
Antimicrob Agents Chemother. 2024 May 7:e0161923. doi: 10.1128/aac.01619.
PubMed Abstract available

VEGA AD, DeRonde K, Jimenez A, Piazza M, et al
Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase (bla(VIM)): infection management and molecular analysis.
Antimicrob Agents Chemother. 2024;68:e0147423.
PubMed Abstract available

KHALID SA, Abd Algaffar S, Tajuddeen N, Lombe BK, et al
Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma-en route to broad-spectrum antimycetomal drugs.
Antimicrob Agents Chemother. 2024;68:e0161223.
PubMed Abstract available

HAYNES AS, Wei Z, Anderson P, Scheetz MH, et al
Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.
Antimicrob Agents Chemother. 2024;68:e0018224.
PubMed Abstract available

MILLER AA, Moussa SH, McLeod SM
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).
Antimicrob Agents Chemother. 2024;68:e0169823.
PubMed Abstract available

MARTINS-GONCALVES T, Pimenta JS, Fontana H, Esposito F, et al
Acinetobacter baumannii international clone 2 co-producing OXA-23, NDM-1, and ArmA emerging in South America.
Antimicrob Agents Chemother. 2024;68:e0029824.
PubMed

CHEN L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, et al
In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2024;68:e0017424.
PubMed Abstract available

GEBREMARIAM T, Alkhazraji S, Gu Y, Najvar LK, et al
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Antimicrob Agents Chemother. 2024;68:e0154523.
PubMed Abstract available

PHAM J, Benefield RJ, Baker N, Lindblom S, et al
In vitro activity of omadacycline against clinical isolates of Nocardia.
Antimicrob Agents Chemother. 2024;68:e0168623.
PubMed Abstract available

MUHLEN S, Heroven AK, Elxnat B, Kahl S, et al
Infection and antibiotic-associated changes in the fecal microbiota of C. rodentium varphistx2(dact)-infected C57BL/6 mice.
Antimicrob Agents Chemother. 2024;68:e0005724.
PubMed Abstract available

BARCELO IM, Escobar-Salom M, Cabot G, Perello-Bauza P, et al
Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications.
Antimicrob Agents Chemother. 2024;68:e0131523.
PubMed Abstract available

SUZUKI D, Sakurai A, Wakuda M, Suzuki M, et al
Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2024;68:e0167223.
PubMed Abstract available

NIELSEN TK, Petersen IB, Xu L, Barbuti MD, et al
The Spx stress regulator confers high-level beta-lactam resistance and decreases susceptibility to last-line antibiotics in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2024 May 1:e0033524. doi: 10.1128/aac.00335.
PubMed Abstract available

YU W, Ju Y, Han X, Tian X, et al
Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124.
PubMed Abstract available

April 2024

BEN-SHMUEL A, Glinert I, Sittner A, Bar-David E, et al
Doxycycline, levofloxacin, and moxifloxacin are superior to ciprofloxacin in treating anthrax meningitis in rabbits and NHP.
Antimicrob Agents Chemother. 2024 Apr 30:e0161023. doi: 10.1128/aac.01610.
PubMed Abstract available

PETRAITIS V, Petraitiene R, Kavaliauskas P, Naing E, et al
Development of rabbit models of ventilator-associated bacterial pneumonia produced by carbapenem-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2024 Apr 30:e0020524. doi: 10.1128/aac.00205.
PubMed Abstract available

SHAFER WM, Conn GL
Ensuring a sustained workforce to combat antibiotic resistance in the 21st century: the critical need for training the next-gen of scientists at the pre-doctoral level.
Antimicrob Agents Chemother. 2024 Apr 19:e0024424. doi: 10.1128/aac.00244.
PubMed Abstract available

HARTUIS S, Ourliac-Garnier I, Robert E, Albassier M, et al
Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.
Antimicrob Agents Chemother. 2024 Apr 16:e0002224. doi: 10.1128/aac.00022.
PubMed Abstract available

KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
PubMed Abstract available

LOSSOUARN J, Beurrier E, Bouteau A, Moncaut E, et al
The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method.
Antimicrob Agents Chemother. 2024 Apr 9:e0143923. doi: 10.1128/aac.01439.
PubMed Abstract available

POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185.
PubMed Abstract available

WEI X, Gao J, Zhou D, Xu C, et al
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential.
Antimicrob Agents Chemother. 2024;68:e0153923.
PubMed Abstract available

ASLAM S, Roach D, Nikolich MP, Biswas B, et al
Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases.
Antimicrob Agents Chemother. 2024;68:e0172823.
PubMed Abstract available

GSCHWIND R, Petitjean M, Fournier C, Lao J, et al
Inter-phylum circulation of a beta-lactamase-encoding gene: a rare but observable event.
Antimicrob Agents Chemother. 2024;68:e0145923.
PubMed Abstract available

XUE J, Li W, Zhao Y, Wang L, et al
Antibiotic-induced ROS-mediated Fur allosterism contributes to Helicobacter pylori resistance by inhibiting arsR activation of mutS and mutY.
Antimicrob Agents Chemother. 2024;68:e0167923.
PubMed Abstract available

RIBEIRO DOS SANTOS A, Gade L, Misas E, Litvintseva AP, et al
Bimodal distribution of azole susceptibility in Sporothrix brasiliensis isolates in Brazil.
Antimicrob Agents Chemother. 2024;68:e0162023.
PubMed Abstract available

TAIT JR, Anderson D, Nation RL, Creek DJ, et al
Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2024;68:e0108123.
PubMed Abstract available

YANO H, Hayashi W, Kawakami S, Aoki S, et al
Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan.
Antimicrob Agents Chemother. 2024 Apr 2:e0166923. doi: 10.1128/aac.01669.
PubMed Abstract available

March 2024

LOCKE JB, Pillar CM, Castanheira M, Carvalhaes CG, et al
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584.
PubMed Abstract available

MAIA AR, Cezard A, Fouquenet D, Vasseur V, et al
Preventive nasal administration of flagellin restores antimicrobial effect of gentamicin and protects against a multidrug-resistant strain of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2024 Mar 25:e0136123. doi: 10.1128/aac.01361.
PubMed Abstract available

SEGAWA T, Masuda K, Hisatsune J, Ishida-Kuroki K, et al
Genomic analysis of inter-hospital transmission of vancomycin-resistant Enterococcus faecium sequence type 80 isolated during an outbreak in Hiroshima, Japan.
Antimicrob Agents Chemother. 2024 Mar 20:e0171623. doi: 10.1128/aac.01716.
PubMed Abstract available

SUN L, Zhuang H, Chen M, Chen Y, et al
Vancomycin heteroresistance caused by unstable tandem amplifications of the vanM gene cluster on linear conjugative plasmids in a clinical Enterococcus faecium.
Antimicrob Agents Chemother. 2024 Mar 20:e0115923. doi: 10.1128/aac.01159.
PubMed Abstract available

LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010.
PubMed Abstract available

VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al
Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC.
Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275.
PubMed Abstract available

HILLIARD JJ, Jakielaszek C, Mannino F, Hossain M, et al
Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.
Antimicrob Agents Chemother. 2024;68:e0149723.
PubMed Abstract available

HOSODA K, Koyama N, Shigeno S, Nishimura T, et al
Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease.
Antimicrob Agents Chemother. 2024;68:e0091723.
PubMed Abstract available

ZHANG X, Wang Y, Li S, Xie F, et al
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem.
Antimicrob Agents Chemother. 2024;68:e0154123.
PubMed Abstract available

ANDRE C, Van Camp AG, Ung L, Gilmore MS, et al
Characterization of the resistome and predominant genetic lineages of Gram-positive bacteria causing keratitis.
Antimicrob Agents Chemother. 2024;68:e0124723.
PubMed Abstract available

DUREJA C, Rutherford JT, Pavel FB, Norseeda K, et al
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.
Antimicrob Agents Chemother. 2024;68:e0122223.
PubMed Abstract available

SALILLAS S, Raaijmakers J, Aarnoutse RE, Svensson EM, et al
Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model.
Antimicrob Agents Chemother. 2024;68:e0115723.
PubMed Abstract available

KOTTOM TJ, Carmona EM, Limper AH
Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy.
Antimicrob Agents Chemother. 2024;68:e0075623.
PubMed Abstract available

CARUSO L, Mellini M, Catalano Gonzaga O, Astegno A, et al
Hydrogen sulfide production does not affect antibiotic resistance in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2024 Mar 6:e0007524. doi: 10.1128/aac.00075.
PubMed Abstract available

February 2024

SARANGI J, Ido A, Ito M, Iinuma C, et al
Clinical isolates of Streptococcus mitis/oralis-related species with reduced carbapenem susceptibility, harboring amino acid substitutions in penicillin-binding proteins in Japan.
Antimicrob Agents Chemother. 2024 Feb 28:e0117923. doi: 10.1128/aac.01179.
PubMed Abstract available

OLIVENCA F, Pires D, Silveiro C, Gama B, et al
Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586.
PubMed Abstract available

BASSERES E, Eubank TA, Begum K, Alam MJ, et al
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.
Antimicrob Agents Chemother. 2024 Feb 16:e0162123. doi: 10.1128/aac.01621.
PubMed Abstract available

January 2024

JIANG X, Li D, Sun Z, Lu Y, et al
Type I BREX system defends against antibiotic-resistant plasmids in Escherichia coli.
Antimicrob Agents Chemother. 2024 Jan 30:e0112823. doi: 10.1128/aac.01128.
PubMed Abstract available

IOVLEVA A, McElheny CL, Fowler EL, Cober E, et al
In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
Antimicrob Agents Chemother. 2024 Jan 30:e0125823. doi: 10.1128/aac.01258.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum